The Good Hope Net project uses Russian
supercomputer to develop treatment against coronavirus infection

Education and Training

Oct 1970/Feb 1975: Degree in Physics - Regulation of bacteriophage T4 gene expression Università degli Studi di Napoli "Federico II" Naples Italy.

Research Interest has been focused for more than ten years on translating the understanding of the molecular basis of neoplastic transformation into the design of selective highly potent RNA-based therapeutics and diagnostic tools. By using living cells as complex target for the SELEX technology I first demonstrated the possibility to generate aptamers that inhibit key transmembrane receptors involved in cancer progression (including, EGFR, AXL, PDGFR, IR, EphB). The central goal of my research program is to develop synthetic targeted RNA reagents (aptamers and miRNAs) to (a) elucidate signaling pathways that regulate pathological proliferation and promote cell survival; (b) modulate signaling in cells for therapeutic intervention; and (c) image targeted delivery of therapeutic agents in vivo.

As an internationally recognized expert in oligonucleotide therapeutics and delivery, Vittorio de Franciscis was the first to demonstrate that RNA aptamers can be used to deliver therapeutic miRNAs and antimiR, to target cancer cells. He continue to pioneer efforts to optimize the aptamer delivery technology and have developed novel cell-based methodologies to implement the broad application of the aptamer delivery approach in different cancer types (including NSCLC, GBM, ovarian cancer, multiple myeloma, BC and melanoma). With the aim to interfere with multiple cancer pathways with a single multifunctional reagent, the primary research effort in his laboratory is dedicated to the selective targeting of therapeutic siRNAs/miRNAs to cancer celltypes/tissues in vivo. This approach has been adopted to develop a combined strategy to selectively target the GBM stem-like cell population with aptamer-miRNA and siRNA therapeutic conjugates. This precision medicine approach is expecting to reduce or eliminate off-target effects, while increasing safety and therapeutic efficacy of treatments. In addition, these multifunctional inhibitors are coupled with imaging and/or sensing capabilities to facilitate tracking of delivery and assessment of therapeutic efficacy and safety.

Professional Experience

• 2018 - present: Senior Collaborator Research Director, Ist. di Endocrinologia e Oncologia Sperimentale – CNR.
• 2006 – 2018: Research Director, Istituto di Endocrinologia e Oncologia Sperimentale – CNR.
• 2001 – 2006: Research Associate, Istituto di Endocrinologia e Oncologia Sperimentale – CNR.
• 1986 – 1996: Research Scientist, Istituto di Endocrinologia e Oncologia Sperimentale – CNR.

Awards

• 20 Oct 2017 – Innocentive Challenge # 9933015: Development of targeted oligonucleotide delivery.
• 16 Sep 2014 – Innocentive Challenge # 9933013: Targeted Delivery of Oligonucleotides.

Other Positions and Organization Experience

• 2007— present: Member, The New York Academy of Sciences, USA.
• 2010 – 2012: Study Section Committee, French National Research Agency (ANR), France.
• 2010 — present: Scientific Advisory Board, BioTecknet Regional Network in Industrial Biotechnology, Italy.
• 2011 — present: Academic Editorial Board, PLoS One, Public Library of Science Publishing Group.
• October 2013: Chair, International Conference on Aptamers in Medicine and Perspectives, Naples, Italy.
• October 2013: Co-Chair, 9th Conference of Oligonucleotide Therapeutic Society, Naples, Italy.
• March 2015: Chair, International Conference, Aptamer 2015, Oxford, UK.
• May 2015: Co-Chair, Special International Symposium celebrating the 25th Anniversary of SELEX by American Society of Gene & Cell Therapy (ASGCT), New Orleans, Louisiana, USA.
• May 2018: co-Chair “New Applications for glioblastoma treatment”, Naples, Italy.
• May 2019: Chair, Local Network Meeting of the Oligonucleotide Therapeutic Society, “Targeted delivery to cancer cells: an emerging aspect of oligo-therapeutic”, Naples, Italy.

Relevant previous projects or activities

• 2016 –2018: Italian Association for Cancer Research (A.I.R.C.) 5x1000 Molecular Clinical Oncology Extension Program # 9980. “Phase I studies of LNA-i-miR-221 and LNA Gapmer 17-92 inhibitor in refractory multiple myeloma patients”. Role: co-PI.
• 2015 – 2018: Bracco Research ”Aptamers for imaging”.
• 2013 – 2015: Italian Association for Cancer Research (A.I.R.C.) IG 2012 # 13345. Role: PI.
• 2013 – 2015: San Paolo Foundation Grant # 2011.1172. Role: PI.
• 2011 – 2015: Italian Ministry of University and Research MERIT RBNE08YFN3. Role: PI and National Coordinator.
• 2006 – 2009: Italian Ministry of University and Research - FIRB International Project Italy USA, (RBINO4J4J7). Role: PI.
• 2004 – 2009: Responsible partner of the Network of Excellence of the 6th FP of EC “European Molecular Imaging Laboratories. Role: PI.
• 2000 – 2003: 5th FP of EC (QLG1−2000−00562) “Oligonucleo􀆟de aptamers for in vivo imaging”. Role: PI.
• 1997 – 2000: Italian Ministry of University and Research Targeted Project "BIOTECNOLOGY". Role: PI.

Publications 2016 – 2020:

1. Quirico L, Orso F, Esposito CL, Bertone S, Coppo R, Conti L, Catuogno S, Cavallo F, de Franciscis V, Taverna D. Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression. Int J Biol Sci. 2020 Feb 10;16(7):1238-1251. doi: 10.7150/ijbs.39768. eCollection 2020.
2. Catuogno S, Di Martino MT, Nuzzo S, Esposito CL, Tassone P, de Franciscis V. An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery. Mol Ther Nucleic Acids. 2019 Dec 6;18:981-990. doi: 10.1016/j.omtn.2019.10.021. Epub 2019 Oct 28.
3. Affinito A, Quintavalle C, Esposito CL, Roscigno G, Vilardo C, Nuzzo S, Ricci-Vitiani L, De Luca G, Pallini R, Kichkailo AS, Lapin IN, de Franciscis V, Condorelli G.The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells. Mol Ther Nucleic Acids. 2019 Dec; 18:99-109. doi: 10.1016/j.omtn.2019.08.015. Epub 2019 Aug 22.
4. Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F, Galasso M, Volinia S, Fiorelli A, Esposito CL, Nuzzo S, Inghirami G, de Franciscis V, Condorelli G Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Mol Ther Nucleic Acids. 2018 Dec 7;13:334-346. doi: 10.1016
5. Esposito CL, Catuogno S, Condorelli G, Ungaro P, de Franciscis V. Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives. Genes (Basel). 2018 Oct 31;9(11). pii: E529
6. Catuogno S, Esposito CL, Ungaro P, de Franciscis V. Nucleic Acid Aptamers Targeting Epigenetic Regulators: An Innovative Therapeutic Option. Pharmaceuticals (Basel). 2018 Aug 24;11(3).
7. Catuogno S, Esposito CL, Condorelli G, de Franciscis V. Nucleic acids delivering nucleic acids. Advmedikament Deliv Rev. 2018 Apr 6.
8. Esposito CL, Nuzzo S, Catuogno S, Romano S, de Nigris F, de Franciscis V. STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma. Mol Ther Nucleic Acids. 2018 Mar 2;10:398-411
9. Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids. 2017 Dec 15;9:251-262.
10. Novara C, Chiadò A, Paccotti N, Catuogno S, CL, Condorelli G, de Franciscis V, Geobaldo F, Rivolo P and Giorgis F. SERS-active metal-dielectric nanostructures integrated in microfluidic devices for label-free quantitative detection of miRNA. Faraday Discuss. 2017 Dec 4;205:271-289.
11. de Franciscis V. Challenging cancer targets for aptamer delivery. Biochimie. 2017 Sep 28.
12. Voccia D, Sosnowska M, Bettazzi F, Roscigno G, Fratini E, de Franciscis V, Condorelli G, Chitta R, D'Souza F, Kutner W, Palchetti I. Direct determination of small RNAs using a biotinylated polythiophene impedimetric genosensor. Biosens Bioelectron. 2017 Jan 15;87:1012-1019
13. Toulmé JJ, Giangrande PH, Mayer G, Suess B, Ducongé F, Sullenger B, de Franciscis V, Darfeuille F, Peyrin E. Aptamers in Bordeaux, 24-25 June 2016. Pharmaceuticals (Basel). 2017 Jan 20;10(1).
14. Thiel WH, Esposito CL, Dickey DD, Dassie JP, Long ME, Adam J, Streeter J, Schickling B, Takapoo M, Flenker KS, Klesney-Tait J, de Franciscis V, Miller FJ Jr, Giangrande PH. Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation. Mol Ther. 2016 Apr;24(4):779-787.
15. Iaboni M, Fontanella R, Rienzo A, Capuozzo M, Nuzzo S, Santamaria G, Catuogno S, Condorelli G, de Franciscis V, Esposito CL. Targeting Insulin Receptor with a Novel Internalizing Aptamer. Mol Ther Nucleic Acids. 2016 Sep 20;5(9):e365
16. Catuogno S, Esposito CL, de Franciscis V.Aptamer-Mediated Targeted Delivery of Therapeutics: An Update. Pharmaceuticals (Basel). 2016 Nov 3;9(4).
17. Esposito CL, Nuzzo S, Kumar SA, Rienzo A, Lawrence CL, Pallini R, Shaw L, Alder JE, Ricci-Vitiani L, Catuogno S, de Franciscis V. A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells. J Control Release. 2016 Sep 28;238:43-57
18. Iaboni M, Russo V, Fontanella R, Roscigno G, Fiore D, Donnarumma E, Esposito CL, Quint Vittorio de Franciscis avalle C, Giangrande PH, de Franciscis V, Condorelli G. Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. Mol Ther Nucleic Acids. 2016 Mar 8;5:e289
19. Amero P, Esposito CL, Rienzo A, Moscato F, Catuogno S, de Franciscis V. Identification of an Interfering Ligand Aptamer for EphB2/3 Receptors. Nucleic Acid Ther. 2016 Jan 29
20. Catuogno S, Esposito CL, de Franciscis V.

Studies:

• 1985-1988 Pre-doctoral fellow, Dipartimento di Biologia e Patologia Cellulare e Molecolare
• July1985 - October 1985 Summer student, Joslin Diabetes Center, Harvard Medical School, Boston
• July 1988 M.D. Summa cum Laude and Honors for Thesis, Naples Medical School
• 1989-91 Fellow Centro di Endocrinologia ed Oncologia Sperimentale, C.N.R.  Dipartimento di Biologia e Patologia Cellulare e Molecolare
• 1990-1993 Post-doctoral Fellow Joslin Diabetes Center, Harvard Medical School, Boston, USA
• October 1995 Ph.D. in Cellular and Molecular Biology and Pathology
• October 1997 Certified Officially for Endocrinology and Metabolic Diseases
• July 1995- November 2002 C.N.R. Research Associate, IEOS (Istituto di Endocrinologia ed Oncologia Sperimentale) Naples, Italy
• November 2002 to 2018: Associate Professor of General Pathology “Federico II” University of Naples, Naples, Italy
• March 2018 to date Full Professor of General Pathology “Federico II” University of Naples, Naples, Italy

Reviewer for grants:

• European Union; Spanish Ministry of Health;
• ANR (Association Nationell Research, France);
• Cariparo Foundation;
• AICR;
• Cariplo Foundation;
• Latvia government;
• Regione Toscana, Italy,
• INSERM.

Reviewer of scientific papers for: Blood, British Journal of Cancer, BBC genetics, Cancer Research, Cell physiol Biochem, Cell Death and Differentiation, Chromosomes and Cancer, Cell Research, Cell Health and Cytoskeleton, Cancers, European Journal of Pharmacology, Expert Opinion on Biological Therapy, Endocrine related cancer research, European J. Pharmacology, Frontier oncology, Genes, Genome Biology, International Journal of Cancer, Intern Journal of Biochem, Molecular Cancer Therapeutics, Molecular Carcinogenesis, Molecular neurobiology, Marine medikaments, Molecules, Molecular Biology Report, Molecular Therapy- NA, Molecular Oncology,Nature Report, Nucleic Acid Research, Journal of Cellular Physiology, Pharmacogenetics and Genomics, J of Nephrology, J of Pathology, Pharmacogenomics, Scientific Reports, Oncogene, Plos Biology, PlosOne, Tumor Biology,

Patents:

1. "A neutralizing RNA aptamer against PDGFR beta and the use thereof in the therapy and diagnosis of hyperproliferative diseases" # EP 12187483.8 (Inventors: V de Franciscis, Laura Cerchia, G. Condorelli)
2. “Method for obtaining oligonucleotide aptamers and uses thereof” # EP 08 105 194.8 Sept 1st 2008 (Inventors: V de Franciscis, Laura Cerchia, G. Condorelli)
3. Apamers against Glioblastoma, (Inventors Gerolama Condorelli, Alessandra Affinito, Cristina Quintavalle) # 10201900006850

Grants:

• MIUR (Italian Ministry of Research) 2001-2003
• Italian Ministry of Health 2002-2004
• NoE, EMIL (European Molecular Imaging Laboratories) 2004-2009
• MIUR-PRINN 2004-06
• FIRB 2005-2008
• AIRC (Italian Association of Cancer Research) 2006-2009
• FIRB 2008-2011-MEdical Research in ITaly" MERIT
• AIRC (Italian Association of Cancer Reserach) 2010-2013
• Berlucchi Foundation, 2013
• AIRC (Italian Association of Cancer Research) 2014-2016
• AIRC (Italian Association of Cancer Research) 2016-2019
• Grant earlier foundation 2017-2019
• H2020-MSCA-RISE-2019, Prisar2
• H2020-MSCA-RISE-2019, Concrete

Academic:

Teaching courses on: General Pathology, Molecular Pathology, Physiopathology

International activities:

• Responsible for the Erasmus program for Medical Biotechnology, coordinator of more than 30 different Erasmus agreements with Federico II University.
  
• Coordinator for Medical Biotechnology of the Joint degree EMJM Biosciences and Bioengineering Innovations for Precision Medicine [BeinPM] by Erasmus mundus call (2019- 2024).
  
• Coordinator of the KA107 mobility program for Medical Biotechnology.

Main research interest:

• microRNA in human cancer.
• Cancer stem cells.
• Non coding RNA: aptamers isolation as specific targeting molecules in cancer stem cells.
• Tumor microenvironment: role of cancer-associated fibroblast-breast cancer cells cross-talk in the cancer phenotype.
• Cancer -released exosomes: their use as cancer liquid biopsy tool.

PUBLICATIONS

1. Condorelli G., Formisano P., Villone G., Smith R.J., and Beguinot F., (1989): Insulin and IGF I stimulate phosphorylation of a Mr 175,000 cytoskeleton-associated protein in intact FRTL5 cells. J. Biol. Chem. 264: 12633-12638.
2. Formisano, P., Condorelli, G., Condorelli, G.L., and Beguinot, F., (1991): Antiphosphotyrosine immunoprecipitation of an insulin-stimulated receptor phosphatase activity from FRTL5 cells. Endocrinology 128: 2949-2957.
3. Condorelli G., Formisan P., Miele C., and Beguinot F., (1992): Thyrotropin Regulates Insulin-Dependent Phosphorylation and Kinase Activity of Insulin and Insulin-Like Growth Factor I Receptors in FRTL5 Cells. Endocrinology 130: 1615-1625.
4. Condorelli, G., Bueno, R., and Smith, R.J., (1994): Two alternatively spliced forms of the human Insulin-like Growth Factor I receptor have distinct biological activities and internalization kinetics in transfected CHO cells. J. Biol. Chem. 269: 8510-8516.
5. Rubattu, S., Enea, I., Ganten, D., Salvatore, D., Condorelli, G., Condorelli, G.L., Russo, R., Romano, M., Gigante, B., Trimarco, B., Volpe, M., (1994): Enhanced adrenal renin and aldosterone biosynthesis during sodium restriction in TGR (mREN2)27 rats. Am. J. Physiol. 267: 515-520
6. Goodyear, L.J., Giorgino, F., Balon, T.W., Condorelli, G., and Smith, R.J., (1995): Effects of contractile activity on insulin receptor and IRS-1 tyrosine phosphorylation and phosphatidylinositol 3-kinase activity in rat skeletal muscle. Am. J. Physiol. 268: E987-E995
7. Miele, C., Formisano, P., Condorelli, G., Caruso, M., Bifulco, G., Oliva, A., Riccardi, G. and Begiunot, F. (1997): Abnormal glucose transport and GLUT-1 cell surface content in fibroblasts from NIDDM and obese subjects. Diabetologia 40:421-429. IF: 5.177
8. Caruso, M., Miele, C., Formisano, P., Condorelli, G., Bifulco, G., Auricchio, R., Riccardi, G., Capaldo, B., and Beguinot, F. (1997): In skeletal muscle, glucose storage and oxidation are differentially impaired by the IR1152 mutant receptor. J. Biol. Chem. 272:7290-7297
9. Volpe, M., Gigante, B., Enea, I., Porcellini, A., Russo, R., Lee, M.A., Magri, P., Condorelli, G., Savoia, C., Lindpaintner, K., Rubattu, S. (1997): Role of tissue renin in the regulation of aldosterone biosynthesis in the adrenal cortex in nephrectomized rats. Circ. Res. 81:857-864
10. Chow, J. C., Condorelli, G., and Smith R.J. (1998): Insulin-like growth factor I receptor internalization regulates signaling via the Sch/Map kinase pathway, but not the insulin receptor substrate 1 pathway. J. Biol. Chem. 273:4672-4680.
11. Formisano, P., Oriente, F., Miele, C., Caruso, M., Auricchio, R., Vigliotta, G., Condorelli, G., and Beguinot, F. (1998): In NIH-3T3 fibroblasts, insulin receptor interaction with specific protein kinase C isoforms controls receptor intracellular routing. J.Biol. Chem. 273: 13197-13202.
12. Condorelli, G., Vigliotta, G., Iavarone, C., Caruso, M., Tocchetti, C.G., Andreozzi, F., M.F. Tecce, Cafieri, A., Formisano, P., Beguinot, L., and Beguinot, F. (1998): PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. Embo J. 17:3858-65
13. Miele, C., Caruso, M., Calleja, V., Auricchio, R., Oriente, F., Formisano, P., Condorelli, G., Cafieri, A., Sawka-Verhelle, D., Van Obberghen, E., and Beguinot, F. (1999): Differential role of insulin receptor substrate (IRS)-1 and IRS-2 in L6 skeletal muscle cells expressing the Arg1152-Gln insulin receptor. J.Biol. Chem. 274: 3094-3102.
14. Condorelli, G,Vigliotta G , Cafieri, A, Trencia, A., Andalò, P, Caruso M, Miele, C., Oriente, F., Formisano, P., and Beguinot, F. (1999): PED/PEA-15: a novel DED-containg protein that inhibits FAS/TNF-R1 mediated apoptosis. Oncogene 18:4409-4415
15. Caruso, M., Miele, C., Oriente, F., Maitan, A., Bifulco, G., Andreozzi, F., Condorelli, G., Formisano, P., and Beguinot, F. (1999): In L6 skeletal muscle cells, glucose induces cytosolic translocation of Protein Kinase C-alfa and trans-activates the insulin receptor kinase. J. Biol. Chem. 274: 28637-28644.
16. Morisco, C., Condorelli, G., Orzi, F., Vigliotta, G., Colangelo, V., Beguinot, F., Trimarco, B., and Lembo, G., (2000): Molecular basis of impaired insulin-stimulated cardiac glucose utilization in spontaneously hypertensive rats. J. of Hypertension 18:465-473. IF:3.039
17. Formisano, P., Oriente, F., Fiory, F., Caruso, M., Miele, C., Maitan, A., Andreozzi, F., Vigliotta, G., Condorelli, G., and Beguinot, F. (2000): Insulin-activated PKCbeta bypasses Ras and stimulates MAPKinase activity and cell proliferation in muscle cells. Mol. Cell. Biol. 20:6323-6333
18. Hao, C., Beguinot, F., Condorelli, G., Trencia, A., Chen, H.T., Van Meir, E.G., Yong, V.W., Parney, I.F., Roa, W.H., and Petruk, K.C. (2001) Induction and intracellular regulation of TRAIL-induced apoptosis in human malignant glioma cells Cancer Res. 61: 1-9
19. Condorelli, G., Trencia, A., Vigliotta, G., Perfetti, A., Goglia U., Cassese A., Musti A., Formisano P., and Beguinot, F. (2002) Multiple members of the mitogen activated protein kinase family are necessary for PED/PEA-15 anti-apoptotic function J. Biol. Chem. 277:11013-11018
20. Condorelli G, Morisco C, Latronico MV, Claudio PP, Dent P, Tsichlis P, Condorelli G, Frati G, Drusco A, Croce CM, Napoli C. (2002) TNF-alpha signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-alpha receptor. FASEB J., 13:1732-7.,
21. Trencia, A., Perfetti, A., Cassese A., Vigliotta, G., Miele, C., Oriente, F., Santopietro, S., Giacco, F., Condorelli, G., Formisano, P. and Beguinot, F. (2003) Protein Kinase B/AKT binds and Phosphorylates PED/PEA-15, stabilizing its antiapoptotic action, Mol. Cell. Biol. 23:4511-4521
22. Briguori, C, Condorelli G, Airoldi F. Mikhail GW, Ricciarelli B, Colombo A. (2004) Impact of glycaemic and lipid control on outcome after percutaneous coronary interventions in diabetic patients. Heart, 90(12):1481-1482
23. Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R. (2004) Double level of protection from death receptors and inflammatory cytokines in neural stem (primitive neural) cells, J. Exp. Med. 200(10):1257-66.
24. Briguori, C, Condorelli G, Airoldi F. Mikhail GW, Bruno Ricciarelli B, Colombo A. (2005) Impact of microvascular complications on outcome after coronary stent implantations in diabetic patients, JACC, 45(3):464-6.
25. Morisco C., Condorelli G, Trimarco V. Bellis A. Marrone C. Condorelli GL, Sadoshima J. Trimarco B: (2005) AKT mediates the cross-talk between beta adrenergic and insulin receptors in neonatal cardiomyocytes. Circulation Research, 96:180-188
26. Briguori, C, Colombo A., Airoldi F., Focaccio A., Iakovou I., Chieffo A., Mikhail GW, Montorfano M, Bonizzoni E., Ricciarelli B, and Condorelli G (2005). Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. Am. Heart J., 150:807-13
27. Stassi G, Garofalo M., Zerilli M , Ricci-Vitiani L., Zanca C, Todaro M., Aragona F., Limite G., Petrella G. and Condorelli G. (2005) PED mediates AKT dependent chemoresistance in human breast cancer cells, Cancer Research, 65:6668-6675,
28. Todaro M, Zerilli M, Patti M, Ricci-Vitiani L., Perez Alea M, Florena AM, Miceli M, Condorelli G., Bonventre S., Di Gesù G., De Maria R., Stassi G. (2006) Autocrine production of IL-4 and IL-10 is required for survival and growth of thyroid cancer cells, Cancer Research. 66(3):1491-9
29. Briguori C, Testa U, Colombo A, Petrucci E, Condorelli G, Airoldi F, Peschle C, Condorelli G. Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. Am J Cardiol. 2006 97(4):472-6.
30. Garofalo M, Romano G., Quintavalle C., Romano MF, Chiurazzi F, Zanca C, and Condorelli G. (2007) PED controls B-chronic lymphocytic leukaemia cell apoptosis and enhances TRAIL sensitivity, Int. J. Cancer 120(6):1215-22
31. D'Alessio A., Cerchia L., Amelio I, Incoronato M., Condorelli G., and de Franciscis V. (2007) Shp2 in PC12 cells: NGF versus EGF signalling. Cellular Signalling, 19:1193-1200
32. Briguori C, Condorelli G, Airoldi F, Focaccio A, D'Andrea D, Cannavale M, Abarghouei AA, Giordano S, De Vivo F, Ricciardelli B, Colombo A. Comparison of coronary medikament-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. Am J Cardiol. (2007); 99(6):779-84.
33. Garofalo M., Quintavalle C., Di Leva G., Zanca C., Romano G., Taccioli C., Liu C.G., Croce C.M., and Condorelli G. MicroRNA signatures of TRAIL resistance in human non small cell lung cancer. Oncogene (2008) Jun 19;27(27):3845-55.
34. Todaro M., Lombardo Y., Perez Alea M., Francipale M.G., Di Stefano A.B., Iovino F., Cammareri P., Agrusta A., Hass T.L., Condorelli G., Walczak H., and Stassi G. Apoptosis resistance in ethithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death and Differentiation (2008) Cell Death Differ. 2008 Apr;15(4):762-72. (ISN 1350-9047)
35. Zanca C., Garofalo M., Quintavalle C., Romano G., Acunzo M., Ragno P.,Montuori N., Incoronato M., Tornillo L., Baumhoer D., Briguori C., Terracciano L., and Condorelli G. PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer (2008) J Cell Mol Med. Vol 12, No6A, 24-16-2426
36. Romano G. ,Briguori C., Quintavalle C., Zanca C., Rivera N. V., Colombo A., and Condorelli G. Contrast agents and renal cell apoptosis (2008), Romano G, Briguori C, Quintavalle C, Zanca C, Colombo A, and Condorelli G. Contrast agents and renal cells apoptosis (2008) Eur Heart J. 29(20):2569-76.
37. Garofalo M, Condorelli G, and Croce M (2008) MicroRNAs in diseases and medikament response. Current Opinion in Pharmacology, 8(5):661-7.
38. Obradovic D, Zanca C, Vogl A, Trümbach D, Deussing J, Condorelli G, Rein T. Vitamin D(3) signalling in the brain enhances the function of Phosphoprotein Enriched in Astrocytes-15 KDa (PEA-15). (2009) J Cell Mol Med. 9999, (999A): 2007-13
39. Garofalo M, Condorelli GL, Croce C. and Condorelli G. MicroRNAs as regulators of death receptors signalling. (2009) Cell Death and Differentiation, 17(2):200-8.
40. Insabato l, Amelio I, Quarto M, Zannetti A, Tolino F, de Mauro G, Cerchia L, Riccio P, Baumhoer D, Condorelli G, Terracciano L, de Franciscis V. SHP-1 tyrosine phosphatase defines a subset of high grade breast tumors. Oncology 2010, 77(6):378-84.
41. Garofalo G, Di Leva G, Romano G, Nuovo G, Suh S, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM. MiR-221&222 regulate TRAIL-resistance and enhance tumorigenicity through PTEN and TIMP3 down-regulation. Cancer Cell (2009) Dec 8;16(6):498-509. *Condorelli G and Croce C are co-corresponding authors
42. Briguori C,Testa, U, Riccioni R, Colombo A, Petrucci E, Condorelli G, Mariani G, D’Andrea D, De Micco F, Rivera NV, Puca AA, Peschle C, and Condorelli G. (2010) Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB J. 24(6):1981-8.
43. Incoronato M, Garofalo M, Urso L, Romano G , Quintavalle C, Zanca C, Iaboni M, Nuovo G, Croce CM 5, and Condorelli G miR-212 increases TRAIL sensitivity in non- small cell lung cancer by targeting the anti-apoptotic protein PED (2010) Cancer Res, 70(9):3638-46.
44. Zanca C, Cozzolino F, Quintavalle C, Di Costanzo S, Lucia Ricci-Vitiani L, Santoriello M, Monti M, Pucci P, and Condorelli G PED interacts with Rac1 and regulates cell migration/invasion processes in human non-small cell lung cancer cells. (2010) J Cell Physiol. Oct;225(1):63-72.
45. Briguori C, Quintavalle C, De Micco F, Condorelli G. (2011) Nephrotoxicity of contrast media and protective effects of acetylcysteine. Arch Toxicol. 85(3):165-73.
46. Briguori C, Airoldi F, Visconti V, Focaccio A, Caiazzo G, Golia B, Biondi-Zoccai G, Ricciarelli B., Condorelli G Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial A Randomized Comparison of 3 medikament-Eluting Stents in Diabetic Patients- (2011) Circ Cardiovasc Interv. 4(2):121-9.
47. Briguori C, Visconti G, Ricciardelli B, Condorelli G. (2011). Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. EuroIntervention 6(9):1117-22
48. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G (2011) Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.REMEDIAL II Investigators. Circulation. 2011 Sep 13;124(11):1260-9. Epub 2011 Aug 15.
49. Catuogno S, Esposito CL, Quintavalle C, Cerchia L, Condorelli G, and de Franciscis V (2011) Recent Advance in Biosensors for microRNAs Detection in Cancer. Cancer, 3 (2), 1877-1898
50. Quintavalle C, Brenca M, De Micco F, Fiore D, Romano S, Romano MF, Apone F, Bianco A, Zabatta MA, Troncone G, Briguori C, Condorelli G. (2011) In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis. Cell death and disease, May 12;2:e155.
51. Quintavalle C, Garofalo M, Zanca C, Romano R, Iaboni M, del Basso De Caro M, J. Carlos Martinez-Montero, Incoronato M, Nuovo G, Croce CM, and Condorelli G. miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphatase PTPmu. Oncogene, (2011) Jul 11. doi: 10.1038/onc.2011.280. [Epub ahead of print]
52. Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, Bottoni A, Garofalo M, Gasparini P, Condorelli G., Chiariello M, and Croce CM. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221&222. Oncogene, (2011) Jun 27. doi: 10.1038/onc.2011.260. [Epub ahead of print]
53. Esposito CL, Passaro D, Longobardo I, Condorelli G, Marotta P, Affuso A, de Franciscis, Cerchia L (2011) A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death. PLoS ONE 6(9): e24071. doi:10.1371/journal.pone.0024071
54. Quintavalle C, Garofalo M, Croce CM, Condorelli G."ApoptomiRs" in vascular cells: Their role in physiological and pathological angiogenesis. Vascul Pharmacol. 2011 Jul 27. [Epub ahead of print]
55. Incoronato M, Urso L, Portela A, Laukkanen MO, Soini Y, Quintavalle C, Keller S, Esteller M, Condorelli G. Epigenetic regulation of miR-212 expression in lung cancer. PLoS One. 2011;6(11):e27722. Epub 2011 Nov 15.
56. Garofalo M, Romano G, Di leva, G., Apollinaire N, Nuovo G, Sun J, Alder, H, Fernandez Cymering C, Condorelli G, Acharya S, Volinia S, and Croce CM (2011) EGFR and MET induce tumorigenesis and gefitinib resistance in lung cancers by controlling microRNA expression. Nature Medicine, 2011 Dec 11;18(1):74-82.
57. Garofalo M, Quintavalle C, Romano G, Croce CM, and Condorelli G (2012) miR221/222 in cancer: their role in tumor progression and response to therapy. Current Molecular Medicine. 2012 Jan;12(1):27-33.
58. Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene. 2012 Feb 27. doi: 10.1038/onc.2012.51.
59. Catuogno S, Esposito CL, Quintavalle C, Condorelli G, de Franciscis V, Cerchia L. Nucleic acids in human glioma treatment: innovative approaches and recent results (2012). J Signal Transduct. 2012;2012:735135. Epub 2012 May 21.
60. Briguori, C., Condorelli, G. (2012) Effect of erdosteine on cyclosporine induced chronic nephrotoxicity Nephro-Urology Monthly, 4(2):487-88
61. Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G, Fiore D, De Marinis P, Croce CM, and Condorelli G (2012) Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene advance online publication, 10 September 2012; doi:10.1038/onc.2012.410
62. Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B , Condorelli G, and Carlo M. Croce CM (2012). MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in NSCLC though BIM downregulation. Proc Natl Acad Sci U S A. 2012 Sep 24. [Epub ahead of print] *Condorelli G and Croce C are co-corresponding authors
63. Bettazzi F, Ezat Hamid-Asl E, Esposito CL, Quintavalle C, Formisano N, Laschi s, Catuogno S, Iaboni M, Marrazza G, Mascini M, Cerchia L, de Franciscis V, Condorelli G, Palchetti I. (2012) Electrochemical detection of miRNA-222 using magnetic bead-based bioassay. Analytical and Bioanalytical Chemistry, 2012 Oct 26. [Epub ahead of print]
64. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, Riciardelli B, Donnarumma E, Bianco A, Zabatta MA, Troncone G, Colombo A, Briguori C, and Condorelli G. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation, 2012 Dec 18;126(25):3008-16. Epub 2012 Nov 12.
65. Rivera NV, Carreras Torres R, Roncarati R, Viviani Anselmi C, De Micco F, Mezzelani A, Koch W, Hoppmann P, Kastrati A, Stewart AFR, Chen L, Roberts R, Karssen L, Amin N, Trimarco V,Izzo R, Iccarino G, Condorelli G, Annibale A. Puca, Pagnotta P, Airoldi F, Trimarco B, van Duijn C M, Condorelli GL and Briguori C. Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes. BMC Medical Genetics, (2013) Jan 23;14:11. doi: 10.1186/1471-2350-14-11.
66. Donahue M, Quintavalle C, Chiariello GA, Condorelli G, Briguori C., Endothelial progenitor cells in coronary artery disease. Biol Chem. 2013 Jun 22. pii: /j/bchm.just-accepted/hsz-2013-0110/hsz-2013-0110.xml. doi: 10.1515/hsz-2013-0110. [Epub ahead of print]
67. Quintavalle C, Mangani D, Rossigno G, Romano G, Diaz-Lagares A, Iaboni M, Donnarumma E, Fiore D, De Marinis P, Soini Y, Esteller M, and Condorelli G. miR-221/222 target the DNA methyltransferase MGMT in glioma cells. PLoS One.2013 PLoS One. 2013 Sep 19;8(9):e74466. doi: 10.1371/journal.pone.0074466.
68. Quintavalle C, Donnarumma E, Fiore D, Briguori C and Condorelli G. Therapeutic strategies to prevent contrast-induced acute kidney injury. Curr Opin Cardiol. 2013 Nov;28(6):676-82. doi: 10.1097/HCO.0b013e3283653f41
69. Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, Arcari A, Piscopo G, Cipresso C, Monti MG, De Lorenzo C, Arra C, Condorelli G, Di Lisa F, Maurea N. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail. (2014 )Jan 6. doi: 10.1002/ejhf.50. [Epub ahead of print]
70. Esposito CL, Cerchia L, Catuogno S, de Vita G, Dassie JP, Santamaria G, Swiderski P, Condorelli G, Giangrande PH and de Franciscis V Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Molecular Therapy 2014 Jan 20. doi: 10.1038/mt.2014.5. [Epub ahead of print]
71. Camorani S, Esposito CL, Rienzo A, Catuogno S, Margherita Iaboni M, Condorelli G, de Franciscis V and Cerchia L Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer Molecular Therapy (2 January 2014) | doi:10.1038/mt.2013.300
72. Quintavalle C, Di Costanzo S, Zanca C, Tasset I, Fraldi A, Incoronato M, Mirabelli P, Monti M, Ballabio A., Pucci P, Cuervo AM, and Condorelli G Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells, J. Cell. Physiology, (2014), Jan 29. doi: 10.1002/jcp.24569. [Epub ahead of print
73. Briguori C, Quintavalle C, Donnarumma E, Condorelli G Novel biomarkers for contrast-induced acute kidney injury (2014) BioMed Research International, 2014:568738. doi: 10.1155/2014/568738. Epub 2014 May 29.
74. Briguori C, Napolitano G, Condorelli G. (2014) Statins and contrast-induced acute kidney injury, Coronary Artery Dis. Nov;25(7):550-1. doi: 10.1097/MCA.0000000000000154.
75. Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, Condorelli G, Banfi S, Verde P. miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer (2014), Oncogene, Aug 25;0. doi: 10.1038/onc.2014.267. [Epub ahead of print]
76. Briguori C, Donnarumma E, Quintavalle C, Fiore D, Condorelli G. Contrast-induced acute kidney injury: potential new strategies. Curr Opin Nephrol Hypertens. 2015 Jan 19. [Epub ahead of print] PMID:25602516 [PubMed - as supplied by publisher]
77. Briguori C, Quintavalle C, Napolitano G, Condorelli G (2015) Endothelial Progenitor Cells and Percutaneous Coronary Artery Intervention: Editorial to: "Effect of High Dose Statin Pretreatment on Endothelial Progenitor Cells after Percutaneous Coronary Intervention (HIPOCRATES Study)" by A. Eisen et al. Cardiovasc medikaments Ther. 2015 Feb 25. [Epub ahead of print]
78. Condorelli G., Giangrande PH, and de Franciscis V. Arresting the Colonial Destiny of Metastatic Seeds with DNA Aptamers, Molecular target (2015), Mol Ther. 2015 Jun;23(6):982-4. doi: 10.1038/mt.2015.85.
79. Quintavalle C, Anselmi C, De Micco F, Roscigno G, Visconti G, Golia B, Focaccio A, Ricciardelli B, Perna E, Papa L, Donnarumma E, Condorelli G, and Briguori C, Neutrophil gelatinase-associated lipocalin and contrast-induced acute kidney injury (2015), Circ Cardiovasc Interv. 2015 Sep;8(9). pii: e002673. doi: 10.1161/CIRCINTERVENTIONS.115.002673.
80. Roscigno G, Quintavalle C, Donnarumma E, Puoti I, Diaz-Lagares A, Iaboni M, Fiore D, Russo V, Todaro M, Romano G, Thomas R, Cortino G, Gaggianesi M, Esteller M, Croce CM, Condorelli G MicroRNA-221 acts as stemness promoter in breast cancer cells by targeting DNMT3b, (2015), Oncotarget. 2015 Oct 19. doi: 10.18632/oncotarget.5979. [Epub ahead of print
81. Briguori C, Madonna R, Zimarino M, Calabrò P, Quintavalle C, Salomone M, Condorelli G, De Caterina R. (2016) Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. Cardiovasc medikaments Ther. 2016 Oct;30(5):465-472
82. Fiore D, Donnarumma E, Roscigno R, Iaboni M, Russo V, Affinito A, Adamo A, De Martino F, Quintavalle C,Romano G, Greco A, Ylermi S, Brunetti A, Croce CM, and Condorelli G. miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of N-RAS (2016), Oncotarget. 2016 Jan 21. doi: 10.18632/oncotarget.6968. [Epub ahead of print]
83. Iaboni M, Russo V, Fontanella R, Roscigno G, Fiore D, Donnarumma E, Esposito CL, Quintavalle C, Giangrande PH, de Franciscis V, Condorelli G. Aptamer-miRNA-212 conjugate sensitizes NSCLC cells to TRAIL (2016), Molecular Therapy - Nucleic Acids, 5: p. e289.
84. Iaboni M, Fontanella R, Rienzo A, Capuozzo M, Nuzzo S, Santamaria G, Catuogno S, Condorelli G, de Franciscis V, Esposito CL. (2016) Targeting Insulin Receptor with a Novel Internalizing Aptamer. Mol Ther Nucleic Acids. 2016 Sep 20;5(9):e365. doi: 10.1038/mtna.2016.73.
85. Roscigno G, Puoti I, Giordano I, Donnarumma E, Fiore D, Russo V, Affinito A, Adamo, Quintavalle C , Todaro M , Vivanco dM M, and Condorelli G. MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer, Oncotarget, (2017) Jan 3. doi: 10.18632/oncotarget.14470. [Epub ahead of print
86. Adamo A, Fiore D, De Martino F, Roscigno G, Affinito A, Donnarumma E, Puoti I, Ricci-Vitiani L, Pallini R, Quintavalle C, Condorelli G. RYK promotes the stemness of glioblastoma cells via the WNT/ β-catenin pathway. (2017), Oncotarget. 2017 Jan 9. doi: 10.18632/oncotarget.14564. [Epub ahead of print]
87. Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C, Rienzo A, Piscuoglio S, Thomas R, Condorelli G Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer (2017), Oncotarget, Jan 19. doi: 10.18632/oncotarget.14752. [Epub ahead of print]
88. Madonna R, Renna FV, Lanuti P, Perfetti M, Marchisio M, Briguori C, Condorelli G, Manzoli L, De Caterina R. (2017) The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. PLoS One. 2017 Apr 10;12(4):e0172800. doi: 10.1371/journal.pone.0172800. eCollection 2017
89. Briguori C, Quintavalle C, D'Alessio F, Donahue M, Roscigno G, De Micco F, Focaccio A, Visconti G, Del Vecchio L, Madonna R, De Caterina R, Condorelli G (2017) Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. Int J Cardiol. Jun 27. pii: S0167-5273(17)30049-9. doi: 10.1016/j.ijcard.2017.06.087. [Epub ahead of print]
90. Voccia D, Sosnowska M, Bettazzi F, Roscigno G, Fratini E, De Franciscis V, Condorelli G, Chitta R, D'Souza F, Kutner W, Palchetti I. (2017) Direct determination of small RNAs using a biotinylated polythiophene impedimetric genosensor. Biosens Bioelectron. 2017 Jan 15;87:1012-1019. doi: 10.1016/j.bios.2016.09.058. Epub 2016 Sep 17.
91. Briguori C, Condorelli G (2017) Contrast-Induced Acute Kidney Injury, Int J Cardiol.
92. Briguori C, Quintavalle C, De Micco F, Visconti G, Di Palma V, Napolitano G, Focaccio A, Condorelli G. (2017) Persistent serum creatinine increase following contrast-induced acute kidney injury. Catheter Cardiovasc Interv. 2017 Aug 11. doi: 10.1002/ccd.27239. [Epub ahead of print]
93. Novara C, Chiadò A, Paccotti N, Catuogno S, Esposito CL, Condorelli G, De Franciscis V, Geobaldo F, Rivolo P, Giorgis F (2017) SERS-active metal-dielectric nanostructures integrated in microfluidic devices for label-free quantitative detection of miRNA. Faraday Discuss. 2017 Sep 8. doi: 10.1039/c7fd00140a. [Epub ahead of print]
94. Briguori C, La Balestra N, Condorelli G, Contrast-induced acute kidney injury (2017) J Interven Cardiol. 2017;30:488–490.
95. Quintavalle C, Hindupur S, Quagliata L, Pallante P, Nigro C, Condorelli G, Andersen J, Tagscherer K, Roth W, Beguinot F, Heim M, KY Ng C, Piscuoglio S and Matter M, Phosphoprotein Enriched in Diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib (2017) Cell Death and Disease, 2017 Oct 26;8(10):e3138. doi: 10.1038/cddis.2017.512.
96. Riccio G, Salvatore Antonucci S, Coppola C, D’Avino C, Piscopo G, Fiore D, Maurea C, M Russo M, Rea D, Arra C, Condorelli G, Di Lisa F, Tocchetti CG, De Lorenzo, and Maurea N. Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production Front Physiol. 2018 Feb 6;9:38. doi: 10.3389/fphys.2018.00038. eCollection 2018.
97. Ng CKY, Di Costanzo GG, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, Perrina V, Quintavalle C1, Boldanova T, Wieland S, Marino-Marsilia G, Lanzafame M, Quagliata L, Condorelli G, Matter MS, Tortora R, Heim MH, Terracciano LM1, Piscuoglio S. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann Oncol. 2018 Mar 2. doi: 10.1093/annonc/mdy083. [Epub ahead of print]
98. Romanelli A, Affinito A, Avitabile C, Catuogno S, Ceriotti P, Iaboni M, Modica J, Condorelli G, Catalucci D (2018). An anti-PDGFRβ aptamer for selective delivery of small therapeutic peptide to cardiac cells.PLoS One. 2018 Mar 7;13(3):e0193392. doi: 10.1371/journal.pone.0193392. eCollection 2018.
99. Catuogno S, Esposito CL, Condorelli G, de Franciscis V. (2018) Nucleic acids delivering nucleic acids. Adv medikament Deliv Rev. 2018 Apr 6. pii: S0169-409X(18)30058-9. doi: 10.1016/j.addr.2018.04.006. [Epub ahead of print]
100. Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F, Galasso M, Volinia S, Fiorelli A, Esposito CL, Nuzzo S, Inghirami G, de Franciscis V, Condorelli G. (2018) Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Mol Ther Nucleic Acids. 2018 Dec 7;13:334-346. doi: 10.1016/j.omtn.2018.09.016. Epub 2018 Sep 27.
101. Esposito CL, Catuogno S, Condorelli G, Ungaro P, de Franciscis V. (2018) Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives. Genes (Basel). 2018 Oct 31;9(11). pii: E529. Doi 10.3390/genes9110529
102. Briguori C, Quintavalle C, Donahue M, D'Alessio F, D'Amore C, Signoriello G, Del Vecchio L, De Caterina R, Condorelli G. (2019) Predictors of strut coverage of medikament eluting stent implantation in diabetic patients. Int J Cardiol. 2019 Feb 1;276:61-65. doi: 10.1016/j.ijcard.2018.11.025. Epub 2018 Nov 9.
103. Highly Homogeneous Biotinylated Carbon Nanodots: Red-Emitting Nanoheaters as Theranostic Agents toward Precision Cancer Medicine. Scialabba C, Sciortino A, Messina F, Buscarino G, Cannas M, Roscigno G, Condorelli G, Cavallaro G, Giammona G, Mauro N. ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19854-19866. doi: 10.1021/acsami.9b04925. Epub 2019 May 2
104. Affinito A, Quintavalle C , Esposito CL, Roscigno G, Vilardo C, Nuzzo S, Ricci-Vitiani L, De Luca G, Pallini R, Kichkailo AS , Lapin IN , de Franciscis V, Condorelli G (2019) The Discovery of RNA-Aptamers That Selectively Bind Glioblastoma Stem Cells, Molecular Therapy- Nucleic acid, Mol Ther Nucleic Acids. 2019 Aug 22;18:99-109. doi: 10.1016/j.omtn.2019.08.015. [Epub ahead of print]
105. Ingenito F, Roscigno G, Affinito A, Nuzzo S, Scognamiglio I, Quintavalle C, Condorelli G. The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications. Int J Mol Sci. (2019) Sep 21;20(19). pii: E4687. doi: 10.3390/ijms20194687.
106. Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells. Alessandra Affinito, Cristina Quintavalle, Carla Lucia Esposito, Giuseppina Roscigno, Catello Giordano, Silvia Nuzzo, Lucia Ricci-Vitiani, Iolanda Scognamiglio, Zoran Minic, Roberto Pallini, Maxim V. Berezovski, Vittorio de Francisis, Gerolama Condorelli. Mol Ther Nucleic Acids. 2020 Feb 13;20:176-185. doi: 10.1016/j.omtn.2020.02.005.
107. MiR-216a acts as a negative regulator of breast cancer by modulating stemness properties and tumor microenvironment. Giuseppina Roscigno*, Assunta Cirella*, Alessandra Affinito, Cristina Quintavalle, Iolanda Scognamiglio, Francesco Palma, Francesco Ingenito, Silvia Nuzzo, Francesca De Micco, Antonio Cuccuru, Renato Thomas, and Gerolama Condorelli. Int J Mol Sci. 2020 Mar 27;21(7). pii: E2313. doi: 10.3390/ijms21072313. IF: 4.183

EDUCATION UNIVERSITY

January 2011 Department of Cellular and Molecular Biology and Pathology, L. Califano, University of Naples Federico II, Italy. PhD degree in Molecular Medicine September 2007 Biotechnology Faculty, University of Naples Federico II, Italy. Master degree in Medical Biotechnology, September 2007, mark 110/110 cum Laude (with Honours) December 2005 Biotechnology Faculty, University of Naples Federico II, Italy. Bachelors degree in Medical Biotechnology, mark 110/110 cum Laude HIGH SCHOOL July 2002 Secondary High school (Scientific studies) 100/100, Liceo Scientifico Statale “E.Torricelli”, Somma Vesuviana, Naples, Italy

RESEARCH AND PROFESSIONAL EXPERIENCES

• October 2019 MIUR ASN (National Scientific Qualification) for Associate Professor in Oncology and hematological disease (06/D2)
• April 2019 Post Doc Fellow, Percuros BV, MSCA-IF-2018
• March 2018 Post Doc Fellow, University of Naples Federico II, Naples, Italy
• December 2017 MIUR ASN (National Scientific Qualification) for Associate Professor in General and Clinical Pathology (06/A2)
• 2014-2017 Post-Doctoral Research Fellow Molecular Pathology Unit-Institute of Pathology University Hospital Basel, CH
• February 2012 Professor for ECM course “Biotecnologie Mediche Seminari 2012” to l’ Azienda Ospedaliera Universitaria Santa Maria della Misericordia di Università di Udine, Italy.
• 2011-2013 Assistant Professor in Pathology, Biotechnological Sciences Faculty, Federico II University, Naples, Italy
• 2011 Post-Doctoral Research at Department of Cellular and Molecular Biology and Pathology, L.Califano, University of Naples Federico II, Naples, Italy SDN Foundation fellow, Naples, Italy
• 2008-2011 Doctoral research with Prof Gerolama Condorelli, University Federico II of Naples, Department of Molecular and Cellular Biology and Pathology. PhD Thesis:“Multifunctional role of microRNAs in human glioblastoma”
• 2008-2009 FIXO (Formazione e Innovazione per l’Occupazione) project
• 2005-2007 Master Scientific Research with Prof Gerolama Condorelli, University Federico II of Naples, Department of Molecular and Cellular Biology and Pathology, Master Scientific Thesis:“Characterization of Bcl-w as new interactor of serinthreonin kinase Akt/PkB”.
• July 2006 Summer student at Ohio State University Columbus OHIO, USA, Research topic: The role of microRNAs in TRAIL resistance in human cancer
• 2002-2005 Bachelor Scientific Research with Prof Gerolama Condorelli, University Federico II of Naples, Department of Molecular and Cellular Biology and Pathology. Bachelor Scientific Thesis:“Post transcriptional Silencing of PED through RNA interference”

FELLOWSHIP AND AWARDS

• March 2019 Awarded for MSCA-IF-2018-838988.
• February 2019 Awarded for Pfizer Research Prize 2019.
• March 2014 Awarded for BlanceflorFoundation fellowship (Sweden) kindly declined.
• January 2014 First Positionfor Programma Star Linea di Intervento 2 Federico II Fellowship.
• 2013 Reviewer for YRCA group (Young Researchers at CroAviano) 2012-2013. Aviano, Italy.
• 2012 Travel grant for 20th Euroconference on Apoptosis ECDO (European cell death Organization) Meeting. Rome, Italy.
• 2011 Travel grant for Rome Course Syllabus "Bench to Bedside Translational Molecular Research", July 11-15, Rome. Italy.
• 2010 FIRC (Federazione Italiana Ricerca su Cancro)" Lenino Fontana e Maria Lionello"fellowship.
• 2008 Travel grant for 7th EWCD (European Work Shop on Cell Death) Meeting, Copenhagen, Denmark.
• Travel grant for 6th EWCD (European Work Shop on Cell Death) Meeting, Hauenstein, Germany.

GRANT

• 2017 Co-Applicant KrebsligaBeider Basel: KLbB-4186-03-2017 Mutational Landscape of primary hepatocellular carcinoma and matched metastasis.
• 2017 Co-Applicant Oncosuisse : KFS-4168-02-2017 The role of "phosphoprotein enriched in diabetes' in liver”.
• 2016 Co-Applicant for Oncoswiss Grant GAP-CRG-201602 " IDENTIFICATION OF MECHANISMSTHAT PROMOTE LIVER CANCER”.
• 2015 Co-Applicant for KrebsligaBeider Basel Nr. 17-2016 Identification of miRNAs involved in liver cancer metastasis 22/06/2015.
• 2010-2013 Participant to AIRC grant, Role of microRNAs in human glioma.
• 2008 Participant for FIRB 2008-MEdical Research in ITaly" MERIT:Progetto n. 17103
• 2006-2009: Participant to AIRC Grant PED as a promising target in cancer therapy.

Reviewer for

• PLOSOne Journal since 2013
• The International Journal of Biochemistry & Cell Biology Journal since 2013 Journal of Proteomics & Bioinformatics since 2014
• SLAS Discover since 2017
• Oncotarget since 2016
• Translational Cancer Research Journal since 2017
• Tumor Biology Journal since 2018
• Cell Death and Disease Journal since 2018

Publications list

H index (Scopus)= 23
Total citation (Scopus) = 2137

1. Roscigno G, Cirella A, Affinito A, Quintavalle C, Scognamiglio I, Palma F, Ingenito F, Nuzzo S, De Micco F, Cuccuru A, Thomas R, Condorelli G. miR-216a Acts as a Negative Regulator of Breast Cancer by Modulating Stemness Properties and Tumor Microenvironment. Int J Mol Sci. 2020 Mar 27;21(7). pii: E2313. doi: 10.3390/ijms21072313.
2. Affinito A, Quintavalle C, Esposito CL, Roscigno G, Giordano C, Nuzzo S, Ricci-Vitiani L, Scognamiglio I, Minic Z, Pallini R, Berezovski MV, de Francisis V, Condorelli G. Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells. Mol Ther Nucleic Acids. 2020 Feb 13;20:176-185. doi: 10.1016/j.omtn.2020.02.005.QC is co-corrisponding author
3. Nuzzo S, Roscigno G, Affinito A, Ingenito F, Quintavalle C, Condorelli G. Potential and Challenges ofAptamers as Specific Carriers of Therapeutic Oligonucleotides for PrecisionMedicine in Cancer. Cancers 2019. In press QC is the co-corrisponding author.
4. Ingenito F, Roscigno G, Affinito A, Nuzzo S, Scognamiglio I, Quintavalle C, Condorelli G.The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications.Int J Mol Sci. 2019 Sep 21;20(19). pii: E4687. doi: 10.3390/ijms20194687. QC is the co-corrisponding author.
5. Affinito A, Quintavalle C, Esposito CL, Roscigno G, Vilardo C, Nuzzo S, Ricci-Vitiani L, De Luca G, Pallini R, Kichkailo AS, Lapin IN, de Franciscis V, Condorelli G.The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells.Mol Ther Nucleic Acids. 2019 Aug 22;18:99-109. doi: 10.1016/j.omtn.2019.08.015. The first two authors equally contributed to the study and QC is also the co-corrisponding authors.
6. Pellecchia S, Quintavalle C, Pallante P. The control of tumor progression by circular RNAs: novelprognostic and therapeutic insights resulting from the analysis of the circAGO2/human antigen R complex. Transl Cancer Res 2019. Vol 8, Supplement 2 (March 2019)
7. Briguori C, Quintavalle C, Donahue M, D'Alessio F, D'Amore C, Signoriello G, De Caterina R, Condorelli G.Predictors of strut coverage of medikament eluting stent implantation in diabetic patients- Is only on-clopidogrel platelet reactivity enough? Reply. Int J Cardiol. 2019 May 15;283:95. doi: 10.1016/j.ijcard.2019.02.052.
8. Lackner C, Quagliata L, Cross W, Ribi S, Heinimann K, Paradiso V, Quintavalle C, Kovacova M, Baumhoer D, Piscuoglio S, Terracciano L, Kovac M.Convergent Evolution of Copy Number Alterations in Multi-Centric Hepatocellular Carcinoma.Sci Rep. 2019 Mar 14;9(1):4611. doi: 10.1038/s41598-019-40843-9.
9. Briguori C, Quintavalle C, Donahue M, D'Alessio F, D'Amore C, Signoriello G, Del Vecchio L, De Caterina R, Condorelli G.Predictors of strut coverage of medikament eluting stent implantation in diabetic patients.Int J Cardiol. 2019 Feb 1;276:61-65. doi: 10.1016/j.ijcard.2018.11.025. Epub 2018 Nov 9
10. Briguori C, Quintavalle C, De Micco F, Visconti G, Di Palma V, Napolitano G, Focaccio A, Condorelli G.Persistent serum creatinine increase following contrast-induced acute kidney injury.Catheter Cardiovasc Interv. 2018 Jun;91(7):1185-1191. doi: 10.1002/ccd.27239. Epub 2017 Aug 11.
11. Ng CKY, Di Costanzo GG, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, Perrina V, Quintavalle C, Boldanova T, Wieland S, Marino-Marsilia G, Lanzafame M, Quagliata L, Condorelli G, Matter MS, Tortora R, Heim MH, Terracciano LM, Piscuoglio S.Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.Ann Oncol. 2018 May 1;29(5):1286-1291. doi: 10.1093/annonc/mdy083.
12. Federer-GsponerJR, QuintavalleC, MüllerDC, DietscheT, PerrinaV, LorberT, Juskevicius D, LenkiewiczE ZellwegerT, GasserT, BarrettMT,RentschCA, BubendorfL, RuizC. Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. Journal of Pathology. J Pathol. 2018 May;245(1):74-84. doi: 10.1002/path.5052. Epub 2018 Apr 2. The first two authors equally contributed to the study.
13. Quintavalle C, Hindupur SK, Quagliata L, Pallante P, Nigro C, Condorelli G, Andersen JB, Tagscherer KE, Roth W, Beguinot F, Heim MH, Ng CKY, Piscuoglio S, Matter MS.Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.Cell Death Dis. 2017 Oct 26;8(10):e3138. doi: 10.1038/cddis.2017.512.The first author is also the co-corresponding author.
14. Quagliata L,Quintavalle C, Lanzafame M, Matter MS, Novello C, di Tommaso L, Pressiani T, Rimassa L, Tornillo L, Roncalli M, Cillo C, Pallante P, Piscuoglio S, Ng CK, Terracciano LM.High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.Lab Invest. 2017 Oct 16. doi: 10.1038/labinvest.2017.107. [Epub ahead of print]. The first two authors equally contributed to the study.
15. Briguori C,Quintavalle C, D'Alessio F, Donahue M, Roscigno G, De Micco F, Focaccio A, Visconti G, Del Vecchio L, Madonna R, De Caterina R, Condorelli G.Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study.Int J Cardiol. 2017 Oct 1;244:112-118. doi: 10.1016/j.ijcard.2017.06.087. Epub 2017 Jun 27.The first two authors equally contributed to the study.
16. Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.Mol Carcinog. 2017 Sep;56(9):2146-2157. doi: 10.1002/mc.22671. Epub 2017 May 17.
17. Roscigno G, Puoti I, Giordano I, Donnarumma E, Russo V, Affinito A, Adamo A, Quintavalle C, Todaro M, Vivanco MD and Condorelli G. MiR-24 induceschemotherapyresistance and hypoxicadvantage in breastcancer. Oncotarget. 2017. doi: 10.18632/oncotarget.14470. [Epubahead of print]
18. Rey S, Quintavalle C, Burmeister K, Calabrese D, Schlageter M, Quagliata L, Cathomas G, Diebold J, Molinolo A, Heim MH, Terracciano LM and Matter MS. Liver Damage and Senescence Increases in Patients Developing Hepatocellular Carcinoma. J GastroenterolHepatol. 2017. doi: 10.1111/jgh.13717. [Epub ahead of print] The first two authors contributed equally.
19. Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C, Rienzo A, Piscuoglio S, Thomas R and Condorelli G. Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget. 2017 Mar 21;8(12):19592-19608. doi: 10.18632/oncotarget.14752
20. Adamo A, Fiore D, De Martino F, Roscigno G, Affinito A, Donnarumma E, Puoti I, Ricci-Vitiani L, Pallini R, Quintavalle C and Condorelli G. RYK promotes the stemness of glioblastoma cells via the WNT/ beta-catenin pathway. Oncotarget. 2017 Feb 21;8(8):13476-13487. doi: 10.18632/oncotarget.14564
21. Witzigmann D, Quagliata L, Schenk SH, Quintavalle C, Terracciano LM and Huwyler J. Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention. Hepatol Res. 2016;46:686-96.
22. Sepe R, Piscuoglio S, Quintavalle C, Perrina V, Quagliata L, Formisano U, Terracciano LM, Fusco A and Pallante P. HMGA1 overexpression is associated with a particular subset of human breast carcinomas. J ClinPathol. 2016;69:117-21.
23. Roscigno G, Quintavalle C, Donnarumma E, Puoti I, Diaz-Lagares A, Iaboni M, Fiore D, Russo V, Todaro M, Romano G, Thomas R, Cortino G, Gaggianesi M, Esteller M, Croce CM and Condorelli G. MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b. Oncotarget. 2016;7:580-92.
24. Matter MS, Marquardt JU, Andersen JB, Quintavalle C, Korokhov N, Stauffer JK, Kaji K, Decaens T, Quagliata L, Elloumi F, Hoang T, Molinolo A, Conner EA, Weber A, Heikenwalder M, Factor VM and Thorgeirsson SS. Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. Hepatology. 2016;63:1888-99.
25. Iaboni M, Russo V, Fontanella R, Roscigno G, Fiore D, Donnarumma E, Esposito CL, Quintavalle C, Giangrande PH, de Franciscis V and Condorelli G. Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. MolTher Nucleic Acids. 2016;5:e289.
26. Fiore D, Donnarumma E, Roscigno G, Iaboni M, Russo V, Affinito A, Adamo A, De Martino F, Quintavalle C, Romano G, Greco A, Soini Y, Brunetti A, Croce CM and Condorelli G. miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS. Oncotarget. 2016;7:19531-47.
27. Cacciola NA, Calabrese C, Malapelle U, Pellino G, De Stefano A, Sepe R, Sgariglia R, Quintavalle C, Federico A, Bianco A, UchimuraBastos A, Milone M, Bellevicine C, Milone F, Carlomagno C, Selvaggi F, Troncone G, Fusco A and Pallante P. UbcH10 expression can predictprognosis and sensitivity to the antineoplastic treatment for colorectalcancerpatients. MolCarcinog. 2016;55:793-807.
28. Briguori C, Madonna R, Zimarino M, Calabro P, Quintavalle C, Salomone M, Condorelli G and De Caterina R. Rosuvastatin for Reduction of Myocardial Damage during CoronaryAngioplasty - the Remedy Trial. CardiovascmedikamentsTher. 2016;30:465-472.
29. Andreozzi M, Quintavalle C, Benz D, Quagliata L, Matter M, Calabrese D, Tosti N, Ruiz C, Trapani F, Tornillo L, Fusco A, Heim MH, Ng CK, Pallante P, Terracciano LM and Piscuoglio S. HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with PoorPrognosis and PromotesTumorGrowth and Migration in in vitro Models. Neoplasia. 2016;18:724-731. The first two authors contributed equally.
30. Seibert JK, Quagliata L, Quintavalle C, Hammond TG, Terracciano L and Odermatt A. A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer. Cancer Med. 2015;4:1717-29.
31. Quintavalle C, Anselmi CV, De Micco F, Roscigno G, Visconti G, Golia B, Focaccio A, Ricciardelli B, Perna E, Papa L, Donnarumma E, Condorelli G and Briguori C. Neutrophil Gelatinase-Associated Lipocalin and Contrast-Induced Acute Kidney Injury. CircCardiovascInterv. 2015;8:e002673.
32. Briguori C, Quintavalle C, Napolitano G and Condorelli G. Endothelial Progenitor Cells and Percutaneous Coronary Artery Intervention : Editorial to: "Effect of High Dose Statin Pretreatment on Endothelial Progenitor Cells after Percutaneous Coronary Intervention (HIPOCRATES Study)" by A. Eisen et al. Cardiovasc medikaments Ther. 2015;29:105-6.
33. Briguori C, Donnarumma E, Quintavalle C, Fiore D and Condorelli G. Contrast-induced acute kidney injury: potential new strategies. CurrOpinNephrolHypertens. 2015;24:145-53.
34. Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, Arcari A, Piscopo G, Cipresso C, Monti MG, De Lorenzo C, Arra C, Condorelli G, Di Lisa F and Maurea N. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail. 2014;16:358-66.
35. Quintavalle C, Di Costanzo S, Zanca C, Tasset I, Fraldi A, Incoronato M, Mirabelli P, Monti M, Ballabio A, Pucci P, Cuervo AM and Condorelli G. Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells. J Cell Physiol. 2014;229:1359-68.
36. Quagliata L, Schlageter M, Quintavalle C, Tornillo L and Terracciano LM. Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA). Microarrays (Basel). 2014;3:91-102.
37. Briguori C, Quintavalle C, Donnarumma E and Condorelli G. Novel biomarkers for contrast-induced acute kidney injury. Biomed Res Int. 2014;2014:568738.
38. Quintavalle C, Mangani D, Roscigno G, Romano G, Diaz-Lagares A, Iaboni M, Donnarumma E, Fiore D, De Marinis P, Soini Y, Esteller M and Condorelli G. MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. PLoS One. 2013;8:e74466.
39. Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G, Fiore D, De Marinis P, Croce CM and Condorelli G. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene. 2013;32:4001-8.
40. Quintavalle C, Donnarumma E, Fiore D, Briguori C and Condorelli G. Therapeutic strategies to prevent contrast-induced acute kidney injury. CurrOpinCardiol. 2013;28:676-82.
41. Donahue M, Quintavalle C, Chiariello GA, Condorelli G and Briguori C. Endothelial progenitor cells in coronaryarterydisease. BiolChem. 2013;394:1241-52.
42. Bettazzi F, Hamid-Asl E, Esposito CL, Quintavalle C, Formisano N, Laschi S, Catuogno S, Iaboni M, Marrazza G, Mascini M, Cerchia L, De Franciscis V, Condorelli G and Palchetti I. Electrochemicaldetection of miRNA-222 by use of a magneticbead-basedbioassay. AnalBioanalChem. 2013;405:1025-34.
43. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, del Basso De Caro M, Martinez-Montero JC, Incoronato M, Nuovo G, Croce CM and Condorelli G. miR-221/222 overexpession in human glioblastoma increasesinvasiveness by targeting the proteinphosphatePTPmu. Oncogene. 2012;31:858-68.
44. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, Ricciardelli B, Donnarumma E, Bianco A, Zabatta MA, Troncone G, Colombo A, Briguori C and Condorelli G. Impact of a high loading dose of atorvastatin on contrast-induced acute kidneyinjury. Circulation. 2012;126:3008-16.
45. Quintavalle C and Condorelli G. Dulanermin in cancer therapy: still much to do. Transl Lung Cancer Res. 2012;1:158-9.
46. Garofalo M, Quintavalle C, Romano G, Croce CM and Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. CurrMol Med. 2012;12:27-33.
47. Catuogno S, Esposito CL, Quintavalle C, Condorelli G, de Franciscis V and Cerchia L. Nucleic acids in human glioma treatment: innovative approaches and recent results. J Signal Transduct. 2012;2012:735135.
48. Quintavalle C, Garofalo M, Croce CM and Condorelli G. "ApoptomiRs" in vascular cells: their role in physiological and pathological angiogenesis. VasculPharmacol. 2011;55:87-91.
49. Quintavalle C, Brenca M, De Micco F, Fiore D, Romano S, Romano MF, Apone F, Bianco A, Zabatta MA, Troncone G, Briguori C and Condorelli G. In vivo and in vitro assessment of pathwaysinvolved in contrast media-inducedrenalcellsapoptosis. Cell Death Dis. 2011;2:e155.
50. Incoronato M, Urso L, Portela A, Laukkanen MO, Soini Y, Quintavalle C, Keller S, Esteller M and Condorelli G. Epigeneticregulation of miR-212 expression in lungcancer. PLoSOne. 2011;6:e27722.
51. Catuogno S, Esposito CL, Quintavalle C, Cerchia L, Condorelli G and De Franciscis V. Recent Advance in Biosensors for microRNAsDetection in Cancer. Cancers (Basel). 2011;3:1877-98.
52. Briguori C, Quintavalle C, De Micco F and Condorelli G. Nephrotoxicity of contrast media and protective effects of acetylcysteine. Arch Toxicol. 2011;85:165-73.
53. Zanca C, Cozzolino F, Quintavalle C, Di Costanzo S, Ricci-Vitiani L, Santoriello M, Monti M, Pucci P and Condorelli G. PED interacts with Rac1 and regulates cell migration/invasion processes in human non-small cell lung cancer cells. J Cell Physiol. 2010;225:63-72.
54. Incoronato M, Garofalo M, Urso L, Romano G, Quintavalle C, Zanca C, Iaboni M, Nuovo G, Croce CM and Condorelli G. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res. 2010;70:3638-46.
55. Zanca C, Garofalo M, Quintavalle C, Romano G, Acunzo M, Ragno P, Montuori N, Incoronato M, Tornillo L, Baumhoer D, Briguori C, Terracciano L and Condorelli G. PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer. J Cell Mol Med. 2008;12:2416-26.
56. Romano G, Briguori C, Quintavalle C, Zanca C, Rivera NV, Colombo A and Condorelli G. Contrast agents and renalcellapoptosis. EurHeart J. 2008;29:2569-76.
57. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM and Condorelli G. MicroRNAsignatures of TRAIL resistance in human non-small celllungcancer. Oncogene. 2008;27:3845-55.
58. Garofalo M, Romano G, Quintavalle C, Romano MF, Chiurazzi F, Zanca C and Condorelli G. Selectiveinhibition of PED proteinexpression sensitizes B-cellchroniclymphocyticleukaemiacells to TRAIL-inducedapoptosis. Int J Cancer. 2007;120:1215-22.

Silvia Catuogno is a researcher at the Institute of Experimental Endocrinology and Oncology (IEOS) of the CNR (Naples, Italy). She gained the PhD in Genetics and Molecular Medicine in 2012 at the University of Naples Federico II. During her PhD, Silvia spent a period at “Bellvitge Biomedical Research Institute” in Barcelona (Spain), in the group of the Prof. Manel Esteller, involved in a project focused on the study of miRNAs and epigenetic alterations underlying cancer pathogenesis.

Then, Silvia Catuogno continued her postdoctoral experience at the IEOS until 2018, when she obtained a Research Scientist position. During Silvia’s research experience, she acquired a great expertise in the field of non-coding RNAs, aptamer selection, characterization, development and optimization as innovative anti-cancer inhibitory medikaments or targeted delivery tools for secondary therapeutic agents (i.e. si/miRNAs). This is integrate with a profound theoretical and practical preparation in the field of cancer cell biology, progression and signal transduction. In addition, Silvia Catuogno is the inventor of 4 patents having as an object new aptamers or aptamer-based conjugates for diagnostic and/or therapeutic uses in oncology (WO2020020947 and patent applications filed). In 2017, she won a scientific prize awarded by InnoCentive Inc. for the project entitled “Development of Targeted Oligonucleotide Delivery” (InnoCentive Challenge # 9933015), focused on the development of an innovative aptamer-antisense oligonucleotide (ASO) conjugate for cancer treatment.

Carla Lucia Esposito is currently a researcher at the Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS)-CNR of Naples. She gained my PhD on 2010 at the University of Naples “Federico II”. During my PhD (2007), was for three months at CNRS in France for the development of aptamer-based binding assays.

Carla’s professional experience was further enriched by a collaborative research with the Dana Farber Cancer Institute (laboratory of Prof. G. Draetta) in Boston where she made a short stage (2009) and an EMBO post-doctoral fellowship (2011). Then, Carla Esposito continued her post-Doc experience at IEOS-CNR up to 2018 when she obtained the permanent position.

She has been included in several scientific proposals and international collaborations. From 2014 Carla is having a role of responsible in scientific grants and currently she is beneficiary of a H2020 RISE project (Concrete, #872391) within an interdisciplinary network of internationally recognized researchers. In addition, Carla Esposito is an inventor of 5 patents having as an object new aptamers or aptamer-based conjugates of diagnostic or therapeutic interest in cancer (patent applications granted or filed).

Focus of her research activity is the development of innovative anti-cancer therapies based on nucleic acid-based aptamers. Carla has applied the SELEX technology for the generation of multiple aptamers and have developed these molecules as tools to:

1. specifically recognize cell surface epitopes;
2. identify new biomarkers;
3. antagonize the malignant phenotype;
4. act as delivery carriers for cancer therapeutics (including siRNAs and miRNAs) reducing unwanted off target effects.

Prof. Giorgia Oliviero got her degree in Chemistry in 1997 at the University of Naples Federico II. In the same University she obtained the PhD in medikament sciences in 2002. In 2004 Giorgia was appointed as Researcher in organic chemistry at the Faculty of Biotechnology where she worked until 2012. In January 2013, Giorgia Oliviero moved to the new Department of Pharmacy of University of Naples Federico II, where she worked until December 2016 when Giorgia got the position of Associate Professor at the Department of Molecular Medicine and Medical Biotechnologies.

Prof. Oliviero participates regularly to national and international research projects in tight collaboration with researchers from academia, private companies and research institutes. The most relevant results of her research have been reported on invitation in many scientific symposia.

Currently, Prof. Oliviero’s research activity is mainly focused on the synthesis of quadruplex-forming oligonucleotides and peptide nucleic acids to be used as new medikaments or as innovative diagnostic tools. DNA quadruplexes are non-canonical secondary structures of DNA and RNA that receive much attention for many reasons. First of all, they represent potential targets for medikaments, being present in biologically relevant regions of DNA, such as telomeres, switch regions of immunoglobulins and many gene promoters. Furthermore, DNA quadruplexes have been found in oligonucleotides capable to bind with high specificity and affinity to selected proteins involved in human diseases (DNA aptamers).

In this frame, Prof. Giorgia Oliviero has recently achieved interesting results, such as the design and the synthesis of a novel class of anti-HIV aptamers and new analogues of thrombin-binding aptamer with improved anticoagulant activity. As concerning the development of innovative diagnostic tools, Dr. Oliviero has recently achieved promising results in the direct synthesis of oligonucleotide strands on porous silica supports (PSi). It is well known that PSi supports are suitable for implementation in label-free molecular recognition techniques thanks to their peculiar optical features.

Professor Giorgia Oliviero is the author of more than 100 papers published in international peer-reviewed journals.

Dr. Nicola Borbone was born in Naples on 23/02/1972. He graduated with honors in Chemistry and Pharmaceuticals Technology at the Faculty of Pharmacy of the University of Naples Federico II, discussing a thesis in Organic Chemistry entitled "Influence of the TATA box bending on stability, polarity and binding affinity with the TBP protein", supervisor Prof. Luciano Mayol.

In 1999 he was awarded with the Ph.D. in "Pharmacologically Active Natural Substances" – 15th Cycle – defending his thesis entitled "Isolation and structural characterization of bioactive secondary metabolites from marine and plant organisms ".

In May 2003, Dr. Borbone won a postgraduate two-years scholarship at the department of Chemistry of natural substances, University of Naples Federico II. In February 2006, he got the permanent position of Researcher at the University of Naples Federico II (Organic Chemistry).

In November 2014 and in April 2018, Dr. Nicola Borbone obtained the National Scientific Qualification respectively for the position of Associate Professor and Full Professor of Organic Chemistry.

In October 2019, he got the permanent position of Associate Professor at the Department of Pharmacy of the University of Naples Federico II.

The research activity of Dr. Borbone is focused on the following topics:

1. isolation and structural characterization of secondary metabolites from marine organisms;
2. isolation and structural characterization of bioactive secondary metabolites from plants;
3. design, synthesis and structural studies on nucleosides and oligonucleotides analogues provided with anticancer of anti-HIV activity;
4. synthesis and structural characterization of DNA quadruple helix structures (G-quadruplexes) for technological and pharmacological applications;
5. synthesis and structural characterization of peptide nucleic acids.

In carrying out his research activity, he developed a network of scientific collaborations with colleagues working in public and private research centers both in Italy and abroad. This network got a significant boost in 2009 thanks to the active participation in the European COST (European Cooperation in Science and Technology) Action MP0802 "Self-assembled guanosine structures for molecular electronic devices". Within this program, Dr. Nicola Borbone held an introductory seminar on his research activity (Debrecen, Hungary, March 26, 2009); obtained the funds for the four-months scholarship of his supervised PhD student Valentina D'Atri's (at the "Center for Cancer Research and Cell Biology" of the Queens University of Belfast, UK); made up fruitful scientific collaborations with leading European research groups that have led to the publication of numerous articles on high impact scientific journals; was invited to hold an oral communication at the closing session of the COST Action (Sitges, Spain, 6-8 October 2012).

Starting from October 2011, he has been Visiting Researcher at the University of Helsinki (Finland) in the frame of a continuative collaboration with the Biomedicum (Helsinki University Central Hospital) and with the Faculty of Pharmacy. In particular, in 2016 Dr. Borbone signed a consultancy contract with the ERC Consolidator Grant 2015 awarded Prof. Vincenzo Cerullo in the framework of the research project entitled "Personalized oncolytic vaccines for cancer immunotherapy".

Dr. Nicola Borbone regularly performs peer reviewing activity on behalf of several internationally renowned scientific journals and has acted as an external referee for the selection procedures issued by the Belgian FNRS (Fonds de la Recherche Scientifique). In 2016 Dr. Borbone participated, on behalf of the Italian Minister of University and Research (MIUR), as an auditor for the evaluation campaign Quality of Research (VQR) 2011-2014.

Dr. Borbone's research activity is documented by more than 90 publications in international indexed scientific journals and by several oral and poster communications at national and international specialized conferences.

Education and training

• Starting 01/09/20: H2020-MSCA-Individual Fellowship
• 2019-2020: Assistant professor for technical laboratory classes, Department of Molecular Medicine and Medical Biotechnology, University of Naples.
• 01/01/20-present: Winner of “Post-doctoral Fellowship 2020” form Fondazione Veronesi
• 01/01/19-31/12/19: Winner of “Post-doctoral Fellowship 2019” form Fondazione Veronesi
• February 2018: Biologist Qualifying Examination
• 01/01/18-31/12/18: Winner of “Post-doctoral Fellowship 2018” form Fondazione Veronesi
• 01/01/17-31/12/17: Winner of “Post-doctoral Fellowship 2017” form Fondazione Veronesi
• 01/10/15-30/09/16: Winner of “Role of microRNA in cancer” fellowship, “Department of Molecular Medicine and Medical Biotechnology”, Napoli (Italy) ref. 26
/2015.
• 12/05/2014: Ph.D in Molecular Oncology and Endocrinology, Federico II University, Napoli (Italy).
• 22/11/2011–05/06/2015: Winner of "MERIT RBNE08ECZ_002" Research Fellowship IEOS, CNR, Napoli (Italy).
• 01/03/2011–28/02/2014: Admission at “Doctorate Program in Molecular Oncology and Endocrinology”, Doctorate School in Molecular Medicine, XXVI Cycle,
Department of Molecular Medicine and Medical Biotechnology, Federico II University, Napoli (Italy).
• 26/03/201
0: Master’s degree in Biology with 110/110 cum laude, Faculty of Mathematical, Physical and Natural Sciences, “Federico II” University, Napoli (Italy).
• 23/07/2007: Bachelor's degree in General and Applied Biology with 110/110 cum laude, Faculty of Mathematical, Physical and Natural Sciences, “Federico II”
University, Napoli (Italy).
• July 2004: Scientific Maturity 95/100, Liceo Scientifico Statale “Arturo Labriola”, Napoli (Italy).

Supervising and mentoring activities teaching

• 22/05/19: Theorical lesson for high school students- Fondazione Veronesi project
• 2017-2018: MIUR Alternanza scuola-lavoro project High school “N. Jommelli”, Aversa/ Department of Molecular Medicine and Medical Biotechnology”, Napoli (Italy).
• 08/05/18: Theorical lesson for high school students- Fondazione Veronesi project.
• 2016-2017: MIUR Alternanza scuola-lavoro project High school “N. Jommelli”, Aversa/ Department of Molecular Medicine and Medical Biotechnology”, Napoli (Italy).
• 18/05/17: Theorical lesson for high school students- Fondazione Veronesi project.

Research and professional experience

• 13/05/2014-Present: Post-Doc in Prof. Gerolama Condorelli's laboratory, Department of Molecular Medicine and Medical Biotechnology, Federico II University, Napoli (Italy). Study of microRNAs involved in multiple aspects of breast cancer tumorigenesis and development of organoids culture as new tools for the prediction of breast cancer patient’s outcome.
• February-April 2012: Erasmus placement in Manel Esteller’s laboratory, Institut d’Investigacion Biomedica de Bellvige-Programa d’Epigenetica i Biologia del Cancer (Barcelona-ES). Main Focus: “Study of epigenetic changes in cancer cells”.
• April 2011-February 2014: Admission at “Doctorate Program in Molecular Oncology and Endocrinology”, Doctorate School in Molecular Medicine, XXVI Cycle, Department of Molecular Medicine and Medical Biotechnology, Federico II University, Napoli (Italy). Main Focus: “Developing a research project focused on the role of microRNAs in the regulation of breast cancer stem cells”.
• October 2010-March 2011: Internship in Gerolama Condorelli’s laboratory. Main Focus: “Analysis of the role of microRNAs in breast cancer and glioblastoma progression”.
• October 2009-March 2010: Internship in Girolama La Mantia’s laboratory. Main Focus: “Study of the mutant human homeoprotein Dlx3 gene associated with Tricho Dento Osseus syndrome, in the regulation of p63 levels”.
• July 2007: Internship in Patrizia Contursi’s laboratory. Main Focus: “Cloning and expression of the hyperthermophile Sulfolobus islandicus fagemide pSSvx ORFc68 gene”.

Technical skills and competences

Mammalian cell cultures (primary, continous, stem cells), primary cells isolation from glioma and breast cancer speciments, isolation of immune cells and Endothelial Progenitor cells from human blood, organoids cultures, co-culture, cellular transfections of plasmids, microRNAs and RNAi, MTT Assay, caspase assay, staining with propidium iodide, transwell migration assay, soft agar assay, immunofluorescence, luciferase assay, lentiviral infection of mammalian cells, extraction of RNA and DNA from cells and tissues, PCR, RT-PCR, Real time-PCR, electrophoresis on agarose or acrylamide gel, bacterial cells culture, bacterial trasfromation, cloning, SDS-PAGE and Western Blot, microtome cutting of histological preparations, Methylation specific primers PCR (MSP technique), Bisulfite sequencing technique, FACS analysis.

Selected conference proceedings

• Roscigno G, et al. “Role of microRNA-221 in breast cancer stemness properties” -2013 Joint National PhD Meeting 2013. Gubbio, Italy.
• Roscigno G, et al. “MiR-221 acts as stemness promoter in breast cancer cells by targeting DNMT3b”-2014 FEBS Workshop on Decoding non-coding RNAs in development and cancer. Capri, Italy.
• Roscigno G, et al. “MiR-24 induces apoptosis resistance and hypoxic advantage in breast cancer stem cells” 10th EWCD – Death never Dies – 2016, Fiuggi , Italy.
• Russo Valentina, Iaboni Margherita, Affinito Alessandra, Giuseppina Roscigno et al. “Innovative therapies based on the use of non-coding RNA for non-small-lung cell cancer (NSCLC)” 10th EWCD – Death never Dies – 2016 Fiuggi, Italy.
• Alessandra Affinito, Cristina Quintavalle, Carla Lucia Esposito Giuseppina Roscigno et al. Identification of selective aptamer ligands for glioblastoma stem cells as new therapeutic tools for glioblastoma. 10th EWCD – Death never Dies – 2016 Fiuggi, Italy.
• Giuseppina Roscigno et al. “Organoids: a new tool for the prediction of breast cancer patient’outcome”. AACR Annual Meeting 2018; Chicago, Illinois.
• Alessandra Affinito, Cristina Quintavalle, Maurizio Albero, Claudia Vilardo, Francesco Palma, Giuseppina Roscigno et al. Identification of RNA-aptamers that selectively recognize and affect glioblastoma stem cells. AACR Annual Meeting 2018, Chicago, Illinois.
• Alessandra Affinito, Cristina Quintavalle, Carla Esposito, Giuseppina Roscigno et al. The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2. ESMO 2019 Congress, Barcelona, Spain.
• Giuseppina Roscigno et al. Breast cancer organoids: a new tool for prediction of medikament response and patient ‘outcome. ESMO 2019 Congress, Barcelona, Spain.

Participation in projects:

• Partecipating at the clinical trial-Doctor Briguori Carlo, (Clinica Mediterranea SPA, Via Orazio 5, Napoli): Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study (EudraCT: 2009-013622-17)/
• 2014: collaboration with Doctor Briguori Carlo (Clinica Mediterranea SPA, Via Orazio 5, Napoli)-project "Danno renale indotto da mezzi di contrasto iodinati".
• 2011-2014: FIRB 2008 project -MEdical Research in ITaly MERIT: Project n. 17103 “Sviluppo di metodologie per l’estrazione e l’integrazione delle informazioni diagnostiche finalizzate a definire percorsi clinici terapeutici personalizzati in patologie ad elevato impatto sociale” – Professor Condorelli Gerolama, IEOS “G. Salvatore” – Napoli.
• 2013-2016: “Molecular signatures of human glioblastoma: role of non-coding RNA” IG_14046 financed by AIRC/FIRC years.
• 2016-2019: “Extra-cellular and cellular microRNAs governing the aggressive phenotype of human breast cancer” Project IG_18473 financed by AIRC/FIRC.

Didactic experience

• Assistant professor for technical laboratory classes (1st classified), September 2019 Department of Molecular Medicine and Medical Biotechnology, University of Naples (Italy).
• Designed “Expert in the field” in Human pathology since 2014, Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples.
• Member of Exam Commission “General Physiopathology I”– cod. 51383, since Academic Year 2014/2015 to 2019/2020, Department of Molecular Medicine and Medical Biotechnology, University of Napoli (Italy).
• Member of Exam Commission “Genetic and Molecular Pathology”– cod. 31790 since Academic Year 2014/2015 to 2019/2020, Department of Molecular Medicine and Medical Biotechnology, University of Napoli (Italy).

Organization of international conference:

• “Targeted delivery to cancer cells: an emerging aspect of oligo-therapeutic”, OTS May 2019, Naples, Italy.
• “Update in Glioblastoma” in 2018 in Naples, Italy.

Training, seminars and workshops

• Selected for Italia-USA “Rome Course Syllabus - Bench to Bedside Translational Molecular Research”, Rome, 2011.
• High content imaging user meeting, 2017 TIGEM (Telethon Institute of Genetics and Medicine), Pozzuoli, Italy.
• Miltenyi Biotec Flowlogic: The all-in-one flow cytometry software, 2018, Napoli, Italy.

PUBLICATIONS

1. Roscigno G, Cirella A, Affinito A, Quintavalle C, Scognamiglio I, Palma F, Ingenito F, Nuzzo S, De Micco F, Cuccuru A, Thomas R, Condorelli G. miR-216a Acts as a Negative Regulator of Breast Cancer by Modulating Stemness Properties and Tumor Microenvironment. Int J Mol Sci. 2020 Mar 27;21(7). pii: E2313. doi: 10.3390/ijms21072313.
2. Affinito A, Quintavalle C, Esposito CL, Roscigno G, Giordano C, Nuzzo S, Ricci-Vitiani L, Scognamiglio I, Minic Z, Pallini R, Berezovski MV, de Francisis V, Condorelli G. Mol Ther Nucleic Acids. 2020 Feb 13;20:176-185. doi: 10.1016/j.omtn.2020.02.005. Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells.
3. Nuzzo S*, Roscigno G*, Affinito A*, Ingenito F*, Quintavalle C, Condorelli G. Cancers (Basel). 2019 Oct 10;11(10). pii: E1521. doi: 10.3390/cancers11101521. Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer. *These authors contributed equally to this work.
4. Ingenito F*, Roscigno G*, Affinito A*, Nuzzo S*, Scognamiglio I*, Quintavalle C, Condorelli G. The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications. Int J Mol Sci. 2019 Sep 21;20(19). pii: E4687. doi: 10.3390/ijms20194687. *These authors contributed equally to this work.
5. Affinito A, Quintavalle C, Esposito CL, Roscigno G, Vilardo C, Nuzzo S, Ricci-Vitiani L, De Luca G, Pallini R, Kichkailo AS, Lapin IN, de Franciscis V, Condorelli G. The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells. Mol Ther Nucleic Acids. 2019 Dec 6;18:99-109. doi: 10.1016/j.omtn.2019.08.015.
6. Scialabba C, Sciortino A, Messina F, Buscarino G, Cannas M, Roscigno G, Condorelli G, Cavallaro G, Giammona G, Mauro N. Highly Homogeneous Biotinylated Carbon Nanodots: Red-Emitting Nanoheaters as Theranostic Agents toward Precision Cancer Medicine. ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19854-19866. doi: 10.1021/acsami.9b04925.
7. Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F, Galasso M, Volinia S, Fiorelli A, Esposito CL, Nuzzo S, Inghirami G, de Franciscis V, Condorelli G. Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Mol Ther Nucleic Acids. 2018 Dec 7;13:334-346
8. Ng CKY, Di Costanzo GG, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, Perrina V, Quintavalle C, Boldanova T, Wieland S, Marino-Marsilia G, Lanzafame M, Quagliata L, Condorelli G, Matter MS, Tortora R, Heim MH, Terracciano LM, Piscuoglio S.Genetic profiling using plasma-derived cell-free DNA in therapy-naive hepatocellular carcinoma patients: A pilot study. Ann Oncol. 2018 May 1;29(5):1286-1291.
9. Briguori C, Quintavalle C, D'Alessio F, Donahue M, Roscigno G, De Micco F, Focaccio A, Visconti G, Del Vecchio L, Madonna R, De Caterina R, Condorelli G. Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. Int J Cardiol. 2017 Oct 1;244:112-118. doi: 10.1016/j.ijcard.2017.06.087. Epub 2017 Jun 27.
10. Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C, Rienzo A, Piscuoglio S, Thomas R, Condorelli G. Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget. 2017 Mar 21;8(12):19592-19608.
11. Adamo A, Fiore D, De Martino F, Roscigno G, Affinito A, Donnarumma E, Puoti I, Ricci Vitiani L, Pallini R, Quintavalle C, Condorelli G. RYK promotes the stemness of glioblastoma cells via the WNT/ β-catenin pathway. Oncotarget. 2017 Feb 21;8(8):13476-13487.
12. Roscigno G, Puoti I, Giordano I, Donnarumma E, Russo V, Affinito A, Adamo A, Quintavalle C, Todaro M, Vivanco MD, Condorelli G. MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Oncotarget. 2017 Mar 21;8(12):19507-19521. doi: 10.18632/oncotarget.14470.
13. Diego Voccia, Marta Sosnowska, Francesca Bettazzi, Giuseppina Roscigno, Emiliano Fratini, Vittorio De Franciscis, Gerolama Condorelli, Francis Wallace D' Souza, Wlodzimierz Kutner, Ilaria Palchetti. Direct determination of small RNAs using abiotinylatedpolythiophene impedimetric genosensor. Biosens Bioelectron. 2017 Jan 15;87:1012-1019.
14. Iaboni M, Russo V, Fontanella R, Roscigno G, Fiore D, Donnarumma E, Esposito CL, Quintavalle C, Giangrande PH, de Franciscis V, Condorelli G. Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. Mol Ther Nucleic Acids. 2016 Mar 8;5:e289.
15. Fiore D, Donnarumma E, Roscigno G, Iaboni M, Russo V, Affinito A, Adamo A, De Martino F, Quintavalle C, Romano G, Greco A, Ylermi S, Brunetti A, Croce CM, and Condorelli G. miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of N-RAS. Oncotarget. 2016 Apr 12;7(15):19531-47
16. Roscigno G, Quintavalle C, Donnarumma E, Puoti I, Diaz-Lagares A, Iaboni M, Fiore D, Russo V, Todaro M, Romano G, Thomas R, Cortino G, Gaggianesi M, Esteller M, Croce CM, Condorelli G. MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b. Oncotarget. 2015 Jan 5;7(1):580-92.
17. Cristina Quintavalle, PhD; Chiara Viviani Anselmi, PhD; Francesca De Micco, PhD; Giuseppina Roscigno, PhD; Gabriella Visconti, MD; Bruno Golia, MD; Amelia Focaccio, MD; Bruno Ricciardelli, MD; Enzo Perna, MD; Laura Papa, PhD; Elvira Donnarumma, PhD;Gerolama Condorelli, MD, PhD; Carlo Briguori, MD, PhD. Neutrophil Gelatinase–Associated Lipocalin and Contrast-Induced Acute Kidney Injury. Circ Cardiovasc Interv. 2015;8:e002673
18. Quintavalle C, Mangani D, Roscigno G, Romano G, Diaz-Lagares A, Iaboni M, Donnarumma E, Fiore D, De Marinis P, Soini Y, Esteller M, Condorelli G. MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. PLoS One 2013; 8(9):e74466.
19. Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo G, Fiore D, De Marinis P, Croce CM, Condorelli G. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene 2013;32(34):4001-8.
20. Di Costanzo A, Festa L, Roscigno G, Vivo M, Morasso M, La Mantia G, Calabrò V. A dominant mutation etiologic for human tricho-dento-osseous syndrome impairs the ability of DLX3 to downregulate ΔNp63. J Cell Physiol. 2011 Aug;226(8):2189-97.
21. Francesco Palma, Alessandra Affinito, Giuseppina Roscigno, Iolanda Scognamiglio, Francesco Ingenito, Silvia Nuzzo, Monica Franzese, Mario Zanfardino, Gerolama Condorelli and Cristina Quintavalle. MiR-34c-3p is a positive prognostic marker of KRAS-mutated NSCLC that targets CDK1. Under revision to Cancer Gene Therapy.

Education

• 2014–2018 PhD in Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Italy
• 2009–2013 MSc in Pharmacy with 106/110, Faculty of Pharmacy, Federico II University of Naples, Italy
• 2006–2009 BSc in Pharmaceutical Information with 110/110, Faculty of Pharmacy, Federico II University of Naples, Italy

Professional Experience

• Since 2/2019 Postdoctoral Scientist: Employment for Percuros B.V., based in Leiden, The Netherland and at CNR, IEOS of Naples, Italy
• 2/2018- 1/2019 Postdoctoral Scientist: Condorelli Laboratory, Department of Molecular Medicine and Medical Biotechnology, “Federico II” University of Naples, Italy
• 12/2014–1/2018 PhD student: Condorelli Laboratory, Department of Molecular Medicine and Medical Biotechnology, “Federico II University”, Naples, Italy Main focus: “Identification of selective aptamer ligands for glioblastoma stem cells as new therapeutic tools for glioblastoma”
• 7/2017–11/2017 Erasmus Plus Fellow: ERASMUS PLUS KA107 fellowship, Tutor: Prof. Patrick Arbuthnot Antiviral Gene Therapy Research Unit of the University of the Witwatersrand, Johannesburg, South Africa
• 1/2014–6/2014 Internship: Vittorio de Franciscis’s laboratory, IEOS CNR, Naples, Italy. Main focus: “Development of RNA aptamers using protein-SELEX”
• 01/2012–12/2013 Internship: Vincenzo Santagada’s Laboratory for an experimental thesis on “Pharmaceutical and Toxicological Chemistry” with the title “Design and Synthesis of Phenoxybenzamide Derivatives as Antiprionic Agents”

Publications (H-index 6)

1. Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells. Alessandra Affinito, Cristina Quintavalle, Carla Lucia Esposito, Giuseppina Roscigno, Catello Giordano, Silvia Nuzzo, Lucia Ricci-Vitiani, Iolanda Scognamiglio, Zoran Minic, Roberto Pallini, Maxim V. Berezovski, Vittorio de Francisis, Gerolama Condorelli. Mol Ther Nucleic Acids. 2020 Feb 13;20:176-185. doi: 10.1016/j.omtn.2020.02.005.
   IF: 5.919
2. MiR-216a acts as a negative regulator of breast cancer by modulating stemness properties and tumor microenvironment. Giuseppina Roscigno*, Assunta Cirella*, Alessandra Affinito, Cristina Quintavalle, Iolanda Scognamiglio, Francesco Palma, Francesco Ingenito, Silvia Nuzzo, Francesca De Micco, Antonio Cuccuru, Renato Thomas, and Gerolama Condorelli. Int J Mol Sci. 2020 Mar 27;21(7). pii: E2313. doi: 10.3390/ijms21072313.
   IF: 4.183
3. The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications. Francesco Ingenito*, Giuseppina Roscigno*, Alessandra Affinito*, Silvia Nuzzo*, Iolanda Scognamiglio, Cristina Quintavalle, and Gerolama Condorelli. Int J Mol Sci. 2019 Sep 21;20(19). pii: E4687. doi: 10.3390/ijms20194687.
   IF: 4.183
   Citation: 6
4. Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer. Silvia Nuzzo*, Giuseppina Roscigno*, Alessandra Affinito*, Francesco Ingenito, Cristina Quintavalle, and Gerolama Condorelli. Cancers (Basel). 2019 Oct 10;11(10). pii: E1521. doi: 10.3390/cancers11101521.
   IF: 6.162
   Citation: 2
5. The Discovery of RNA-Aptamers That Selectively Bind Glioblastoma Stem Cells. Alessandra Affinito*, Cristina Quintavalle*, Carla Lucia Esposito, Giuseppina Roscigno, Claudia Vilardo, Silvia Nuzzo, Lucia Ricci Vitiani, Gabriele De Luca, Roberto Pallini, Anna S Kichkailo, Ivan N Lapin, Vittorio de Franciscis, Gerolama Condorelli. doi: 10.1016/j.omtn.2019.08.015. Epub Accepted 2019 August 15
   IF: 5.919
   Citation: 2
6. Aptamer-miR-34c conjugate affects cell proliferation of non-small-cell lung cancer cells. Valentina Russo*, Alessia Paciocco*, Alessandra Affinito, Giuseppina Roscigno, Danilo Fiore, Francesco Palma, Marco Galasso, Stefano Volinia, Alfonso Fiorelli, Carla Lucia Esposito, Silvia Nuzzo, Giorgio Inghirami, Vittorio de Franciscis, Gerolama Condorelli. Molecular Therapy-Nucleic Acids 13, 334-346. doi: 10.1016/j.omtn.2018.09.016. Epub 2018 Sep 27
   IF: 5.919
   Citation: 15
7. An anti-PDGFRβ aptamer for the selective delivery of small therapeutic peptide to cardiac cells. Alessandra Romanelli; Alessandra Affinito; Concetta Avitabile; Silvia Catuogno; Paola Ceriotti; Margherita Iaboni; Geroloma Condorelli; Daniele Catalucci. PLoS One. 2018 Mar 7;13(3):e0193392. doi: 10.1371/journal.pone.0193392. eCollection 2018.
   IF: 2.766
   Citation: 3
8. Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C, Rienzo A, Piscuoglio S, Thomas R, Condorelli G. Oncotarget. 2017 Mar 21;8(12):19592-19608. doi: 10.18632/oncotarget.14752.
   IF: 5.168
   Citations: 121
9. RYK promotes the stemness of glioblastoma cells via the WNT/ β-catenin pathway. Adamo A, Fiore D, De Martino F, Roscigno G, Affinito A, Donnarumma E, Puoti I, Ricci Vitiani L, Pallini R, Quintavalle C, Condorelli G. Oncotarget. 2017 Feb 21;8(8):13476-13487. doi: 10.18632/oncotarget.14564.
   IF: 5.168
   Citations: 21
10. MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Roscigno G, Puoti I, Giordano I, Donnarumma E, Russo V, Affinito A, Adamo A, Quintavalle C, Todaro M, Vivanco MD, Condorelli G. Oncotarget. 2017 Mar 21;8(12):19507-19521. doi: 10.18632/oncotarget.14470.
    IF: 5.168
    Citations: 32
11. MiR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS. Fiore D, Donnarumma E, Roscigno G, Iaboni M, Russo V, Affinito A, Adamo A, De Martino F, Quintavalle C, Romano G, Greco A, Soini Y, Brunetti A, Croce CM, Condorelli G. Oncotarget. 2016 Apr 12;7(15):19531-47. doi: 10.18632/oncotarget.6968.
    IF: 5.168
    Citations: 27

* These authors contributed equally to this work.

Granted patents

1. “Aptamers against Glioblastoma” Inventors Gerolama Condorelli, Alessandra Affinito and Cristina Quintavalle. Italian patent application number IT102019000006850 filed on 15 May 2019.

Invited presentations

• Affinito A, Interaction between industry and academy. OTS meeting, Napoli, Italy (10/05/2019).
• Affinito A, RNA-aptamers that selectively bind and inhibit Glioblastoma Stem Cell. Updates in Glioblastoma, Napoli, Italy (25/05/2018).
• Affinito A, RNA-aptamers and their future role in clinical research, Leiden, The Netherlands (23/07/2018).

Selected conference proceedings (last 3 years)

• The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2 Alessandra Affinito et al. ESMO 2019 Congress, Barcellona, Spain.
• Identification of RNA-aptamers that selectively recognize and affect glioblastoma stem cells Alessandra Affinito et al. AACR Annual Meeting 2018, Chicago, Illinois
• Organoids: a new tool for the prediction of breast cancer patient outcome Giuseppina Roscigno, Assunta Cirella, Alessandra Affinito, et al. AACR Annual Meeting 2018, Chicago, Illinois
• Identification of selective aptamer ligands for glioblastoma stem cells as new therapeutic tools for glioblastoma Alessandra Affinito et al. 10th EWCD – Death never Dies – 2016 Fiuggi, Italy
• MiR-24 induces apoptosis resistance and hypoxic advantage in breast cancer stem cells Giuseppina Roscigno, Ilaria Puoti, Immacolata Giordano, Cristina Quintavalle, Elvira Donnarumma, Danilo Fiore, Valentina Russo, Assunta Adamo, Alessandra Affinito, et al. 10th EWCD – Death never Dies – 2016 Fiuggi, Italy
• Innovative therapies based on the use of non-coding RNA for non-small-lung cell cancer (NSCLC) Russo Valentina, Iaboni Margherita, Affinito Alessandra, et al. 10th EWCD – Death never Dies – 2016 Fiuggi, Italy

Recent example of participation in industrial innovation

• InnoCentive Challenge # 9933015 AstraZeneca Challenge: Development of Targeted Oligonucleotide Delivery. Involvement in Milestone 2 and in challenge solution (Award Issued – 10.01.2018) in collaboration with Prof Vittorio De Franciscis and the IEOS “Center for Experimental Endocrinology and Oncology” of CNR in Naples. Dr Affinito helped to achieve AstraZeneca’s goal by independently planning and executing experiments. The objective of this challenge concerned the development of a targeted therapy for lung cancer cells by using aptamers ability to selectively deliver antisense oligonucleotides (ASOs). Chimera conjugates, consisting of selective aptamers for lung cancer and ASO, where designed and prepared by Dr Affinito. Chimera conjugates were tested on target cells (A549, a model of non-small cell lung cancer) by evaluating cell death, proliferation and migration.

Funding, Prizes and Awards

• 2018: Postdoc fellowship ref. 26/2017 “Molecular Oncology”- Department of Molecular medicine and Medical Biotechnology, Federico II of Naples (February 2018- March 2019)
• 2017: Erasmus Plus Fellow: selection and participation of Erasmus Plus Programme KA107 at the University of the Witwatersrand, Johannesburg (South Africa) from 01/07/2017 to 30/09/2017. Prof. Patrick Arbuthnot and PhD Betty Maepa, at the department of Antiviral Gene Therapy Research Unit of WITS medical school, supervised Dr Affinito training. Internship concerned the inactivation of Hepatitis B Virus Replication in Cultured Cells with Engineered Transcription Activator-Like Effector Nucleases (TALENs)
• 2013: Pharmacist Qualifying Examination

Supervising and mentoring activities and teaching

• As a PhD student as well as postdoctoral research fellow, Dr Affinito has been involved in a day-to-day supervision of several Biotechnology BSc and MSc students at Federico II University of Naples, ensuring their laboratory work and their thesis preparations. She has supervised Erasmus students arrived in Condorelli’s Lab.
• Dr Affinito has been involved in work-linked training of high-school students which included theorical lessons and practical activities.

Communication and outreach activities

• In recent year various supervisors encouraged Dr Affinito to actively engage large audiences and to bring her expert knowledge and expertise about aptamers to the general public. Dr Affinito co-organised previous outreach activities including, e.g. in 2017 ‘Open Day’ with a poster exhibition and practical activities to potentially new students interested in enrolling at Federico II University of Naples.
• In addition, Dr Affinito actively participated in workshops spreading the outcomes of her research to “freshers” of her University to raise scientific awareness about aptamers.

Training, seminars and workshops

• High content imaging user meeting, 2017 TIGEM (Telethon Institute of Genetics and Medicine), Pozzuoli, Italy
• DMMBM-IEOS seminars, weekly seminars with departmental and foreign guests, Napoli, Italy
• Miltenyi Biotec Flowlogic: The all-in-one flow cytometry software, 2018, Napoli, Italy

Didactic experience

• From Academic Year 2015/2016 to 2018/2019 Practical and theoretical teaching activities (10 hours/year) within classes in “Technology for cell lines and stem cells” (University of Napoli, Italy)
• From Academic Year 2015/2016 to 2018/2019 Member of Exam Commission “General Pathology I”– cod. 08906, 50153 University of Napoli (Italy)
• From Academic Year 2015/2016 to 2018/2019 Member of Exam Commission “General Physiopathology I”– cod. 51383 University of Napoli (Italy)
• From Academic Year 2015/2016 to 2018/2019 Member of Exam Commission “Genetic and Molecular Pathology”– cod. 31790 University of Napoli (Italy)

Participation in projects:

• “Extra-cellular and cellular microRNAs governing the aggressive phenotype of human breast cancer” Project IG_18473 financed by AIRC/FIRC years 2016-2019
• “Molecular signatures of human glioblastoma: role of non-coding RNA” IG_14046 financed by AIRC/FIRC years 2013-2016

Co-organization of international conference:

• “Targeted delivery to cancer cells: an emerging aspect of oligo-therapeutic, OTS May 2019, Naples, Italy
• “Update in Glioblastoma” in 2018 in Naples, Italy

Independent thinking and leadership qualities: The numerous examples described in this CV helped Dr Affinito to achieve a sound professional maturity and outline her independent thinking and leadership qualities in detail. Independent thinking:

a) independent planning and execution of experiments: Dr Affinito carried out her PhD project by independently thinking through the experimental design, with minor inputs from her supervisor Prof Condorelli, finally succeeding to finish the project and publish it in 5 peer-reviewed journals,
b) contributions to the training of highly qualified personnel: In recent years, Dr Affinito trained some peer-scientists in various disciplines including laboratory techniques (IHC, Cell culture, Co-cultures, etc.) and health and safety matters (i.e. disposal of hazards chemicals),
c) teaching practical courses for students: During her time at University of Naples, Dr Affinito was responsible for training courses preparing young students for their future careers in academia requiring expertise in chemistry laboratory. A wide range of topics in chemistry and biology were covered. Lectures, testing methods and laboratory exercises were designed by Dr Affinito to promote in-depth understanding, confidence and scientific literacy,
d) experienced the entire process of publishing: By writing papers (and / or parts of it), setting up cover letters, and corresponding with the editorial offices as corresponding author for final publication the applicant experienced the entire publishing process, and
e) diverse research disciplines: From the start of her PhD, Dr Affinito was involved in other on-going projects of the research group and was able to fulfil the objective, also starting new research lines, with key results that allowed their successful completion, demonstrating her great capabilities to work as a contributing team member in a group with researchers from diverse disciplines.

Leadership qualities:

a) initiating fruitful collaborations: Dr Affinito’s willingness in establishing collaborations with other research groups has been advantageous for his professional career, not only for peer-reviewed publications, but also in gaining the possibility to learn from other research fields and, therefore, broaden his scientific knowledge. In recent years, Dr Affinito set up several collaborations for example in the Netherlands providing access and expertise to investigate molecular mechanisms in cancer models,
b) supervising: Over the past years, the Dr Affinito has mentored, advised, trained, and co-supervised undergraduate students on both experimental design and practical / technical aspects of the research. Dr Affinito finds this experience both challenging and enjoyable, and she gained valuable experience in terms of leadership required to promote effective working within a team, and
c) co-organizing conferences and workshops: Dr Affinito organised “Update in Glioblastoma” in 2018 in Naples, Italy